_MEMBER_att_D_no_prior_0 - 0.9-1.1,_MEMBER_att_D_no_prior_0 - 4.5-5.5,_MEMBER_att_D_no_prior_0 - 9.0-11.0,_LogP_att_D_no_prior_0 - 0.9-1.1,_LogP_att_D_no_prior_0 - 4.5-5.5,_LogP_att_D_no_prior_0 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-4.8,-4.6,-4,GO:0002764,immune response-regulating signaling pathway,M111,3,0
1,1,1,-6.9,-5,-3.2,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-4.6,-2.4,-3.7,GO:0050727,regulation of inflammatory response,M111,3,0
1,1,1,-4.6,-5.1,-4.3,GO:0002757,immune response-activating signaling pathway,M111,3,0
1,1,1,-4,-3.5,-5.4,R-HSA-9658195,Leishmania infection,M111,3,0
1,1,1,-4.6,-3.1,-2.4,GO:0009611,response to wounding,M111,3,0
1,1,1,-3.8,-2.8,-3.4,GO:0031349,positive regulation of defense response,M111,3,0
1,1,1,-10,-2.1,-4.2,GO:0022407,regulation of cell-cell adhesion,M111,3,0
1,1,1,-2.1,-3.1,-2.3,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M111,3,0
1,1,1,-3.5,-2.1,-2.9,GO:0031341,regulation of cell killing,M111,3,0
1,1,1,-3.4,-2.6,-3.1,hsa04062,Chemokine signaling pathway,M111,3,0
1,1,1,-2.3,-2.9,-2.6,M10,PID BCR 5PATHWAY,M111,3,0
1,1,1,-6.3,-2.6,-2.8,GO:0050870,positive regulation of T cell activation,M111,3,0
1,1,1,-12,-5.2,-2.5,R-HSA-449147,Signaling by Interleukins,M111,3,0
1,1,1,-4,-2.7,-2.2,GO:0019221,cytokine-mediated signaling pathway,M111,3,0
1,1,1,-3.5,-2.8,-2,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M111,3,0
1,1,1,-7.9,-2.6,-2.7,GO:0051251,positive regulation of lymphocyte activation,M111,3,0
1,1,1,-6.6,-4.8,-2.6,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-6.9,-4.7,-4.9,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-6.5,-3.5,-4.9,GO:0032103,positive regulation of response to external stimulus,M111,3,0
1,1,1,-2.2,-2.6,-4.2,GO:0006909,phagocytosis,M111,3,0
1,1,1,-4.3,-2.7,-2.2,GO:0050866,negative regulation of cell activation,M111,3,0
1,1,1,-8.7,-3.5,-3.6,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-4,-2.8,-2.9,GO:0098657,import into cell,M111,3,0
1,1,1,-5.1,-5.1,-3.6,GO:0002683,negative regulation of immune system process,M111,3,0
1,1,1,-2.4,-2.7,-2.8,M124,PID CXCR4 PATHWAY,M111,3,0
1,1,1,-7.1,-2.6,-2.4,hsa05221,Acute myeloid leukemia,M111,3,0
1,1,1,-4,-3.5,-5.4,R-HSA-9824443,Parasitic Infection Pathways,M111,3,0
1,1,1,-4.6,-3.2,-2.2,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-8.2,-3.7,-3.3,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-4.7,-3.8,-4.8,GO:0002429,immune response-activating cell surface receptor signaling pathway,M111,3,0
1,1,1,-8.7,-4,-3.5,GO:0051249,regulation of lymphocyte activation,M111,3,0
1,1,1,-7.7,-2.1,-2.7,GO:0001819,positive regulation of cytokine production,M111,3,0
1,1,1,-7.6,-5.8,-3.6,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M111,3,0
1,1,1,-4.3,-2.2,-2.1,GO:0046635,positive regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-8.8,-3,-3.9,GO:0002250,adaptive immune response,M111,3,0
1,1,1,-7.4,-5.6,-3.3,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-4.7,-3.7,-2.3,R-HSA-1280218,Adaptive Immune System,M111,3,0
1,1,1,-6.9,-2.5,-2.3,WP5293,Acute myeloid leukemia,M111,3,0
1,1,1,-6.7,-7.3,-4,GO:0001775,cell activation,M111,3,0
1,1,1,-17,-6.3,-3.2,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-7.4,-2.9,-4.1,GO:1903037,regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-3.1,-3.5,-4.5,hsa04662,B cell receptor signaling pathway,M111,3,0
1,1,1,-5.2,-5.1,-2.3,GO:0006954,inflammatory response,M111,3,0
1,1,1,-5,-4.8,-2.8,GO:0050777,negative regulation of immune response,M111,3,0
1,1,1,-2.4,-4.7,-4.5,WP23,B cell receptor signaling pathway,M111,3,0
1,1,1,-3.6,-3.8,-2.3,GO:0002831,regulation of response to biotic stimulus,M111,3,0
1,1,1,-2.7,-4.6,-2,M34,PID TCR PATHWAY,M111,3,0
1,1,1,-5,-2.5,-2.4,GO:0002703,regulation of leukocyte mediated immunity,M111,3,0
1,1,1,-8.9,-4.9,-4.6,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-2.3,-2.9,-2.3,GO:0042060,wound healing,M111,3,0
1,1,1,-3.6,-3.8,-2.2,GO:0050851,antigen receptor-mediated signaling pathway,M111,3,0
1,1,1,-2.9,-3.4,-2.7,GO:0002695,negative regulation of leukocyte activation,M111,3,0
1,1,1,-3,-2.3,-2.7,GO:0051345,positive regulation of hydrolase activity,M111,3,0
1,1,1,-4.1,-2.9,-2.6,GO:0050853,B cell receptor signaling pathway,M111,3,0
1,1,1,-9.4,-2.6,-3.3,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-3.9,-2.1,-2.9,GO:0051336,regulation of hydrolase activity,M111,3,0
1,1,1,-4.4,-2.9,-3.3,WP3929,Chemokine signaling pathway,M111,3,0
1,1,1,-5.6,-5.6,-2.2,GO:0031348,negative regulation of defense response,M111,3,0
1,1,1,-4.3,-2.2,-2.6,hsa05133,Pertussis,M111,3,0
1,1,1,-2.9,-3.2,-2.6,GO:0050728,negative regulation of inflammatory response,M111,3,0
1,1,1,-9.4,-4.4,-3.9,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-3.2,-3.5,-3.1,GO:0051250,negative regulation of lymphocyte activation,M111,3,0
1,1,1,-9.8,-4.9,-5.2,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-2.3,-2.1,-2.8,GO:0045089,positive regulation of innate immune response,M111,3,0
1,1,1,-2.6,-2.7,-2.5,R-HSA-6798695,Neutrophil degranulation,M111,3,0
1,1,1,-7,-2.9,-3,GO:0045087,innate immune response,M111,3,0
1,1,1,-3.4,-2.2,-3.6,GO:0050864,regulation of B cell activation,M111,3,0
1,1,1,-7,-3.4,-3.5,GO:0050863,regulation of T cell activation,M111,3,0
1,1,1,-2.3,-2.3,-3.2,GO:0002833,positive regulation of response to biotic stimulus,M111,3,0
1,1,1,-7.2,-2.6,-3.1,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-2.4,-3.9,-4.4,M8626,SIG BCR SIGNALING PATHWAY,M111,3,0
1,1,1,-2.8,-2.2,-3.4,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M111,3,0
1,1,1,-2,-2.1,-2.2,hsa05203,Viral carcinogenesis,M111,3,0
1,1,1,-6.5,-6.3,-4.2,GO:0002253,activation of immune response,M111,3,0
1,1,1,-3.9,-2.1,-6.1,GO:0002252,immune effector process,M111,3,0
1,1,1,-5.1,-3.4,-4.4,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M111,3,0
1,1,1,-3,-2.3,-4.8,GO:0002861,regulation of inflammatory response to antigenic stimulus,M111,3,0
1,1,1,-11,-7,-2.3,GO:0030097,hemopoiesis,M111,3,0
1,1,0,-2.7,-3.8,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M110,2,0
0,1,1,0,-5,-2.6,M17200,SA B CELL RECEPTOR COMPLEXES,M011,2,0
1,1,0,-6.6,-3.5,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M110,2,0
0,1,1,0,-2.8,-4.3,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M011,2,0
0,1,1,0,-4,-4.6,R-HSA-9664417,Leishmania phagocytosis,M011,2,0
1,1,0,-6.1,-2.1,0,GO:0001568,blood vessel development,M110,2,0
1,1,0,-3.9,-3.5,0,GO:0001501,skeletal system development,M110,2,0
1,0,1,-3.7,0,-4.5,GO:0060627,regulation of vesicle-mediated transport,M101,2,0
1,0,1,-2.1,0,-2.3,GO:0099024,plasma membrane invagination,M101,2,0
1,1,0,-3.3,-2,0,M255,PID HIF1 TFPATHWAY,M110,2,0
1,1,0,-3.9,-2.1,0,M175,PID ERBB2 ERBB3 PATHWAY,M110,2,0
0,1,1,0,-2.1,-3.3,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M011,2,0
1,1,0,-5,-2.2,0,GO:2000147,positive regulation of cell motility,M110,2,0
0,1,1,0,-6.3,-3.9,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M011,2,0
1,1,0,-2.5,-2.3,0,GO:0002832,negative regulation of response to biotic stimulus,M110,2,0
1,1,0,-7.1,-4.1,0,GO:0002521,leukocyte differentiation,M110,2,0
0,1,1,0,-4.3,-4.7,R-HSA-76002,"Platelet activation, signaling and aggregation",M011,2,0
1,0,1,-4.5,0,-2.5,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M101,2,0
1,1,0,-6.4,-3.8,0,hsa04659,Th17 cell differentiation,M110,2,0
1,1,0,-4.4,-2.2,0,GO:0046634,regulation of alpha-beta T cell activation,M110,2,0
1,1,0,-2.4,-2,0,GO:0140467,integrated stress response signaling,M110,2,0
1,1,0,-3.3,-2.8,0,GO:0046638,positive regulation of alpha-beta T cell differentiation,M110,2,0
1,1,0,-4.2,-2.7,0,hsa05417,Lipid and atherosclerosis,M110,2,0
1,0,1,-4.9,0,-2.2,GO:0019724,B cell mediated immunity,M101,2,0
1,1,0,-3,-3.3,0,WP2526,PDGF pathway,M110,2,0
0,1,1,0,-4.8,-4.3,WP286,IL 3 signaling pathway,M011,2,0
0,1,1,0,-3.1,-2.3,GO:0097035,regulation of membrane lipid distribution,M011,2,0
1,1,0,-3,-5.6,0,hsa05170,Human immunodeficiency virus 1 infection,M110,2,0
1,1,0,-4.1,-2.6,0,GO:0030098,lymphocyte differentiation,M110,2,0
1,1,0,-3.5,-2.1,0,hsa05207,Chemical carcinogenesis - receptor activation,M110,2,0
0,1,1,0,-2.2,-4.6,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M011,2,0
1,1,0,-4,-4.7,0,WP4816,TGF beta receptor signaling in skeletal dysplasias,M110,2,0
1,0,1,-5.4,0,-3,GO:0070665,positive regulation of leukocyte proliferation,M101,2,0
1,0,1,-3.5,0,-2.2,GO:0002449,lymphocyte mediated immunity,M101,2,0
1,1,0,-5.2,-3.1,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M110,2,0
1,1,0,-2.2,-2.8,0,WP4357,NRF2 ARE regulation,M110,2,0
1,1,0,-2.5,-3.6,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M110,2,0
0,1,1,0,-3.2,-5.5,hsa04611,Platelet activation,M011,2,0
0,1,1,0,-4.7,-4,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M011,2,0
1,1,0,-2.3,-2.1,0,WP4155,Endometrial cancer,M110,2,0
1,1,0,-3.4,-2.9,0,WP382,MAPK signaling pathway,M110,2,0
1,1,0,-2,-2.1,0,M235,PID TCR CALCIUM PATHWAY,M110,2,0
1,1,0,-2.5,-4,0,CORUM:2695,ETS2-FOS-JUN complex,M110,2,0
1,0,1,-2.4,0,-3.5,GO:0043087,regulation of GTPase activity,M101,2,0
1,0,1,-5,0,-2.6,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M101,2,0
0,1,1,0,-2.7,-3.9,GO:0038094,Fc-gamma receptor signaling pathway,M011,2,0
0,1,1,0,-2.8,-2.7,GO:0006869,lipid transport,M011,2,0
1,1,0,-2.7,-2.5,0,R-HSA-2172127,DAP12 interactions,M110,2,0
1,1,0,-7.5,-6,0,hsa05200,Pathways in cancer,M110,2,0
1,0,1,-3.6,0,-4.9,GO:0150146,cell junction disassembly,M101,2,0
1,1,0,-2.7,-3.3,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M110,2,0
1,1,0,-6.4,-2.9,0,GO:1903706,regulation of hemopoiesis,M110,2,0
1,1,0,-2.5,-3,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M110,2,0
0,1,1,0,-2,-3.2,GO:0050869,negative regulation of B cell activation,M011,2,0
1,1,0,-4.4,-3.1,0,WP710,DNA damage response only ATM dependent,M110,2,0
1,1,0,-2.9,-4.4,0,R-HSA-389356,CD28 co-stimulation,M110,2,0
0,1,1,0,-2.5,-6.5,WP3937,Microglia pathogen phagocytosis pathway,M011,2,0
1,1,0,-3.8,-2.2,0,GO:0002761,regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-4.5,-3.3,0,hsa05210,Colorectal cancer,M110,2,0
1,1,0,-5.8,-3.4,0,GO:1903131,mononuclear cell differentiation,M110,2,0
0,1,1,0,-2.6,-3.4,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M011,2,0
0,1,1,0,-2.4,-2.3,GO:0015748,organophosphate ester transport,M011,2,0
1,1,0,-4,-2.7,0,WP5130,Th17 cell differentiation pathway,M110,2,0
1,1,0,-9.8,-2.9,0,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M110,2,0
1,1,0,-4.9,-2.9,0,GO:1902532,negative regulation of intracellular signal transduction,M110,2,0
1,1,0,-2.8,-2.4,0,GO:0002698,negative regulation of immune effector process,M110,2,0
1,1,0,-6.1,-2.5,0,hsa04936,Alcoholic liver disease,M110,2,0
1,0,1,-2.4,0,-2.1,GO:0050920,regulation of chemotaxis,M101,2,0
1,1,0,-6,-3.6,0,GO:0071559,response to transforming growth factor beta,M110,2,0
1,0,1,-3.8,0,-2.4,GO:0060326,cell chemotaxis,M101,2,0
1,1,0,-2.4,-2.5,0,GO:2000106,regulation of leukocyte apoptotic process,M110,2,0
1,1,0,-3.1,-2.7,0,GO:0045582,positive regulation of T cell differentiation,M110,2,0
1,0,1,-3.4,0,-3.5,M186,PID PDGFRB PATHWAY,M101,2,0
0,1,1,0,-4,-4.6,R-HSA-9664422,FCGR3A-mediated phagocytosis,M011,2,0
1,0,1,-2.1,0,-2.6,GO:0061024,membrane organization,M101,2,0
1,1,0,-2.7,-4.1,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M110,2,0
1,1,0,-8.4,-5.4,0,GO:0030099,myeloid cell differentiation,M110,2,0
1,1,0,-4.2,-3.9,0,GO:0032695,negative regulation of interleukin-12 production,M110,2,0
0,1,1,0,-3.4,-2.4,GO:0045332,phospholipid translocation,M011,2,0
1,1,0,-4.4,-2.8,0,GO:1903708,positive regulation of hemopoiesis,M110,2,0
1,1,0,-2.8,-2.1,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M110,2,0
1,1,0,-2.7,-2.5,0,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,1,0,-3,-4.3,0,R-HSA-388841,Costimulation by the CD28 family,M110,2,0
1,1,0,-2.4,-3.5,0,GO:0016310,phosphorylation,M110,2,0
1,1,0,-4.7,-2.1,0,GO:0040017,positive regulation of locomotion,M110,2,0
1,0,1,-2.4,0,-2.2,GO:1903305,regulation of regulated secretory pathway,M101,2,0
1,1,0,-3.1,-2.1,0,GO:0061919,process utilizing autophagic mechanism,M110,2,0
1,1,0,-4.6,-2.1,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M110,2,0
1,0,1,-2,0,-3.4,GO:0002886,regulation of myeloid leukocyte mediated immunity,M101,2,0
1,1,0,-5.5,-2.1,0,GO:0043408,regulation of MAPK cascade,M110,2,0
1,0,1,-3.6,0,-2.2,GO:0050871,positive regulation of B cell activation,M101,2,0
0,1,1,0,-2.4,-2.4,GO:0031294,lymphocyte costimulation,M011,2,0
1,1,0,-3.1,-2.5,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M110,2,0
1,1,0,-2.9,-2,0,GO:0010506,regulation of autophagy,M110,2,0
1,1,0,-3.3,-2.1,0,WP4844,Influence of laminopathies on Wnt signaling,M110,2,0
1,1,0,-2.1,-2.1,0,hsa04926,Relaxin signaling pathway,M110,2,0
1,0,1,-3.3,0,-3.4,GO:0030100,regulation of endocytosis,M101,2,0
1,1,0,-2.4,-2.4,0,R-HSA-202433,Generation of second messenger molecules,M110,2,0
0,1,1,0,-4.4,-2.4,M88,PID CD8 TCR PATHWAY,M011,2,0
0,1,1,0,-2.5,-2.5,GO:0031295,T cell costimulation,M011,2,0
1,0,1,-4.3,0,-4.2,R-HSA-9013149,RAC1 GTPase cycle,M101,2,0
1,1,0,-3.4,-2.1,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,0,1,-12,0,-3.5,GO:0045785,positive regulation of cell adhesion,M101,2,0
1,0,1,-4.2,0,-5.2,GO:0098883,synapse pruning,M101,2,0
0,1,1,0,-6.6,-2.7,R-HSA-2871796,FCERI mediated MAPK activation,M011,2,0
1,1,0,-3.4,-2.7,0,GO:0051216,cartilage development,M110,2,0
1,1,0,-3.4,-2.9,0,WP231,TNF alpha signaling pathway,M110,2,0
1,1,0,-3.3,-2.2,0,GO:0043068,positive regulation of programmed cell death,M110,2,0
1,0,1,-2,0,-2.3,GO:0051495,positive regulation of cytoskeleton organization,M101,2,0
1,1,0,-4.2,-4.8,0,WP560,TGF beta receptor signaling,M110,2,0
1,1,0,-2.5,-4,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M110,2,0
1,0,1,-4.1,0,-2.4,GO:0030888,regulation of B cell proliferation,M101,2,0
1,1,0,-7.1,-5.1,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M110,2,0
1,0,1,-4.9,0,-2.2,hsa04610,Complement and coagulation cascades,M101,2,0
1,0,1,-2.8,0,-2.3,M33,PID GLYPICAN 1PATHWAY,M101,2,0
1,1,0,-3.7,-4.3,0,GO:0045088,regulation of innate immune response,M110,2,0
1,1,0,-6.8,-6.4,0,WP69,T cell receptor signaling pathway,M110,2,0
0,1,1,0,-2.4,-5,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M011,2,0
1,1,0,-2.1,-2.2,0,WP3668,Hypothesized pathways in pathogenesis of cardiovascular disease,M110,2,0
1,1,0,-2.1,-2.2,0,GO:0034101,erythrocyte homeostasis,M110,2,0
1,1,0,-2.5,-4,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M110,2,0
0,1,1,0,-9.5,-3.7,M7,PID FCER1 PATHWAY,M011,2,0
1,1,0,-6,-2.7,0,GO:0070848,response to growth factor,M110,2,0
0,1,1,0,-3.1,-4.1,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M011,2,0
1,0,1,-2.3,0,-2.4,GO:0006911,"phagocytosis, engulfment",M101,2,0
0,1,1,0,-2.7,-3.9,R-HSA-9674555,Signaling by CSF3 (G-CSF),M011,2,0
1,1,0,-6.5,-2.8,0,hsa05169,Epstein-Barr virus infection,M110,2,0
0,1,1,0,-2.7,-3.9,R-HSA-114604,GPVI-mediated activation cascade,M011,2,0
1,1,0,-3.5,-2.4,0,hsa04010,MAPK signaling pathway,M110,2,0
1,1,0,-4.1,-2.1,0,GO:0045639,positive regulation of myeloid cell differentiation,M110,2,0
1,1,0,-2.6,-2,0,hsa05163,Human cytomegalovirus infection,M110,2,0
1,0,1,-2.7,0,-2.6,WP5090,Complement system in neuronal development and plasticity,M101,2,0
1,1,0,-3.5,-2.4,0,GO:0002700,regulation of production of molecular mediator of immune response,M110,2,0
1,1,0,-5.4,-3.5,0,GO:0032102,negative regulation of response to external stimulus,M110,2,0
1,1,0,-2.6,-3.2,0,WP428,Wnt signaling,M110,2,0
1,0,1,-2.9,0,-2.5,R-HSA-8878159,Transcriptional regulation by RUNX3,M101,2,0
1,1,0,-2.9,-2.6,0,M193,PID NEPHRIN NEPH1 PATHWAY,M110,2,0
1,0,1,-6.4,0,-3.6,R-HSA-9012999,RHO GTPase cycle,M101,2,0
1,1,0,-3.2,-2.4,0,hsa05145,Toxoplasmosis,M110,2,0
0,1,1,0,-2.6,-3.4,R-HSA-9664433,Leishmania parasite growth and survival,M011,2,0
1,0,1,-6,0,-2.3,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M101,2,0
1,1,0,-6,-2.3,0,GO:0071363,cellular response to growth factor stimulus,M110,2,0
1,1,0,-5,-2.2,0,WP2328,Allograft rejection,M110,2,0
1,1,0,-4.3,-3,0,M167,PID AP1 PATHWAY,M110,2,0
1,1,0,-3.8,-2.5,0,GO:0045619,regulation of lymphocyte differentiation,M110,2,0
0,1,1,0,-2.3,-2.8,M99,PID TXA2PATHWAY,M011,2,0
1,1,0,-2.1,-3.6,0,R-HSA-9679191,Potential therapeutics for SARS,M110,2,0
0,1,1,0,-3.1,-4,GO:0002576,platelet degranulation,M011,2,0
1,1,0,-5.6,-3.5,0,M183,PID IL6 7 PATHWAY,M110,2,0
1,0,1,-2.1,0,-3.1,GO:0090630,activation of GTPase activity,M101,2,0
1,1,0,-5.5,-2.2,0,hsa05215,Prostate cancer,M110,2,0
1,1,0,-3.3,-2.3,0,WP5094,Orexin receptor pathway,M110,2,0
1,1,0,-5.6,-2.2,0,GO:0006959,humoral immune response,M110,2,0
1,1,0,-3.7,-2.9,0,WP366,TGF beta signaling pathway,M110,2,0
1,0,1,-4.2,0,-3.5,GO:0051056,regulation of small GTPase mediated signal transduction,M101,2,0
1,1,0,-3.2,-2.2,0,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M110,2,0
1,1,0,-2,-2.1,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M110,2,0
0,1,1,0,-2.4,-2.1,GO:0002758,innate immune response-activating signaling pathway,M011,2,0
0,1,1,0,-6.3,-3.3,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M011,2,0
0,1,1,0,-3.6,-4.6,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M011,2,0
1,0,1,-2.2,0,-2.8,GO:0043300,regulation of leukocyte degranulation,M101,2,0
1,1,0,-3.6,-2.8,0,GO:0042113,B cell activation,M110,2,0
0,1,1,0,-2.2,-3.1,R-HSA-2029481,FCGR activation,M011,2,0
1,0,1,-2,0,-2.2,GO:0006644,phospholipid metabolic process,M101,2,0
1,1,0,-2.4,-2.6,0,GO:0045580,regulation of T cell differentiation,M110,2,0
1,1,0,-5.2,-3.5,0,GO:0042110,T cell activation,M110,2,0
0,1,1,0,-2.6,-2.5,GO:0010876,lipid localization,M011,2,0
1,1,0,-4.3,-3,0,GO:0002062,chondrocyte differentiation,M110,2,0
1,1,0,-3.4,-3.2,0,GO:0046637,regulation of alpha-beta T cell differentiation,M110,2,0
1,0,1,-3.1,0,-3.9,GO:0002443,leukocyte mediated immunity,M101,2,0
1,1,0,-4.5,-2.5,0,R-HSA-9679506,SARS-CoV Infections,M110,2,0
1,0,1,-6.9,0,-2.5,GO:0070663,regulation of leukocyte proliferation,M101,2,0
1,1,0,-3.6,-4.3,0,WP399,Wnt signaling pathway and pluripotency,M110,2,0
0,1,1,0,-2.5,-2.5,GO:0007599,hemostasis,M011,2,0
1,1,0,-5.4,-3.8,0,GO:0009617,response to bacterium,M110,2,0
1,0,1,-4,0,-3,GO:0006897,endocytosis,M101,2,0
0,1,1,0,-4.7,-6.7,hsa04664,Fc epsilon RI signaling pathway,M011,2,0
1,1,0,-3.9,-3.6,0,WP5098,T cell activation SARS CoV 2,M110,2,0
1,1,0,-3.1,-3.7,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M110,2,0
1,1,0,-5.9,-3,0,WP3646,Hepatitis C and hepatocellular carcinoma,M110,2,0
0,1,1,0,-2.1,-2.2,GO:0032735,positive regulation of interleukin-12 production,M011,2,0
1,0,1,-7.2,0,-2.1,GO:0032944,regulation of mononuclear cell proliferation,M101,2,0
1,1,0,-3.3,-2.9,0,GO:0045824,negative regulation of innate immune response,M110,2,0
1,1,0,-2.8,-2.2,0,hsa05225,Hepatocellular carcinoma,M110,2,0
1,1,0,-9.1,-3.1,0,GO:0071345,cellular response to cytokine stimulus,M110,2,0
1,1,0,-6.3,-4.8,0,hsa05142,Chagas disease,M110,2,0
1,1,0,-4.7,-2.9,0,hsa05152,Tuberculosis,M110,2,0
0,1,1,0,-3,-4,R-HSA-109582,Hemostasis,M011,2,0
1,1,0,-7.6,-4.2,0,hsa04380,Osteoclast differentiation,M110,2,0
1,1,0,-2.8,-6.3,0,WP5072,Modulators of TCR signaling and T cell activation,M110,2,0
1,1,0,-4.2,-2.3,0,GO:0045621,positive regulation of lymphocyte differentiation,M110,2,0
1,1,0,-2.4,-3.2,0,GO:0050868,negative regulation of T cell activation,M110,2,0
1,1,0,-3.5,-2.3,0,hsa05130,Pathogenic Escherichia coli infection,M110,2,0
1,1,0,-2,-2.1,0,GO:0071425,hematopoietic stem cell proliferation,M110,2,0
1,1,0,-6.2,-3.2,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-3.9,-2.7,0,GO:0071216,cellular response to biotic stimulus,M110,2,0
1,1,0,-6.1,-5.7,0,hsa04658,Th1 and Th2 cell differentiation,M110,2,0
1,1,0,-2,-3.2,0,M234,PID IL2 STAT5 PATHWAY,M110,2,0
1,1,0,-5.1,-3.1,0,WP5083,Neuroinflammation and glutamatergic signaling,M110,2,0
0,1,1,0,-3.3,-4.8,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M011,2,0
1,1,0,-5.3,-2.9,0,GO:0010720,positive regulation of cell development,M110,2,0
1,1,0,-3.1,-2.1,0,GO:0006914,autophagy,M110,2,0
0,1,1,0,-4,-4.6,R-HSA-9664407,Parasite infection,M011,2,0
1,1,0,-5.2,-2,0,GO:0030335,positive regulation of cell migration,M110,2,0
1,1,0,-2,-2.9,0,GO:0006468,protein phosphorylation,M110,2,0
1,0,1,-3.9,0,-2.3,GO:0001910,regulation of leukocyte mediated cytotoxicity,M101,2,0
0,1,1,0,-3.8,-2.6,M22,PID GMCSF PATHWAY,M011,2,0
1,1,0,-2.6,-2.4,0,hsa05135,Yersinia infection,M110,2,0
0,1,1,0,-2.8,-4.1,R-HSA-912631,Regulation of signaling by CBL,M011,2,0
1,1,0,-4.1,-2.5,0,GO:0002718,regulation of cytokine production involved in immune response,M110,2,0
0,1,1,0,-2.2,-2.3,GO:0045576,mast cell activation,M011,2,0
0,1,1,0,-3,-4.2,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M011,2,0
1,1,0,-6.1,-2.4,0,GO:0002573,myeloid leukocyte differentiation,M110,2,0
0,1,1,0,-3.3,-2.4,GO:0034204,lipid translocation,M011,2,0
1,1,0,-5.1,-5.8,0,hsa04660,T cell receptor signaling pathway,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M110,2,0
1,1,0,-4.4,-2.8,0,GO:1902107,positive regulation of leukocyte differentiation,M110,2,0
0,1,1,0,-3,-2.2,hsa04730,Long-term depression,M011,2,0
1,0,1,-2.6,0,-2.2,GO:1902905,positive regulation of supramolecular fiber organization,M101,2,0
1,1,0,-2.3,-2,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M110,2,0
1,0,1,-4.1,0,-2.5,GO:0032479,regulation of type I interferon production,M101,2,0
1,0,1,-5.1,0,-2.3,GO:0016064,immunoglobulin mediated immune response,M101,2,0
1,1,0,-5.2,-3,0,GO:1902105,regulation of leukocyte differentiation,M110,2,0
1,1,0,-2.3,-2,0,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-3.9,-2.1,0,GO:0032653,regulation of interleukin-10 production,M110,2,0
0,1,1,0,-2.6,-3.5,GO:0019370,leukotriene biosynthetic process,M011,2,0
1,0,1,-4.8,0,-2.6,R-HSA-194315,Signaling by Rho GTPases,M101,2,0
1,1,0,-3.4,-3.3,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M110,2,0
1,0,1,-2.1,0,-2.3,GO:0010324,membrane invagination,M101,2,0
0,1,1,0,-2.2,-3.1,GO:0038095,Fc-epsilon receptor signaling pathway,M011,2,0
0,1,1,0,-2.2,-4.6,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M011,2,0
1,1,0,-4.3,-5.8,0,GO:0032655,regulation of interleukin-12 production,M110,2,0
1,1,0,-3.5,-2.1,0,R-HSA-877300,Interferon gamma signaling,M110,2,0
1,0,0,-2.5,0,0,WP5199,PtdIns 4 5 P2 in cytokinesis pathway,M100,1,0
0,0,1,0,0,-2.7,hsa00590,Arachidonic acid metabolism,M001,1,0
1,0,0,-3,0,0,GO:0045732,positive regulation of protein catabolic process,M100,1,0
1,0,0,-3.2,0,0,GO:1903587,regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,M100,1,0
1,0,0,-3.5,0,0,GO:0031329,regulation of cellular catabolic process,M100,1,0
1,0,0,-3.2,0,0,R-HSA-5684996,MAPK1/MAPK3 signaling,M100,1,0
1,0,0,-2.7,0,0,R-HSA-372790,Signaling by GPCR,M100,1,0
0,1,0,0,-2.8,0,GO:0016045,detection of bacterium,M010,1,0
0,0,1,0,0,-3.3,M141,PID PI3KCI PATHWAY,M001,1,0
1,0,0,-2.6,0,0,GO:0061377,mammary gland lobule development,M100,1,0
1,0,0,-2.8,0,0,GO:0110053,regulation of actin filament organization,M100,1,0
0,1,0,0,-2.6,0,GO:0071417,cellular response to organonitrogen compound,M010,1,0
1,0,0,-2.8,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M100,1,0
1,0,0,-2.8,0,0,R-HSA-166166,MyD88-independent TLR4 cascade,M100,1,0
0,1,0,0,-2.4,0,R-HSA-4641265,Repression of WNT target genes,M010,1,0
1,0,0,-2.1,0,0,GO:0001701,in utero embryonic development,M100,1,0
0,1,0,0,-2.2,0,GO:0050817,coagulation,M010,1,0
1,0,0,-2.4,0,0,WP673,ErbB signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0071902,positive regulation of protein serine/threonine kinase activity,M100,1,0
0,1,0,0,-2.5,0,GO:2001234,negative regulation of apoptotic signaling pathway,M010,1,0
1,0,0,-2.1,0,0,GO:0050858,negative regulation of antigen receptor-mediated signaling pathway,M100,1,0
1,0,0,-3.2,0,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M100,1,0
1,0,0,-5.5,0,0,GO:1902895,positive regulation of miRNA transcription,M100,1,0
1,0,0,-2.3,0,0,M1718,SIG IL4RECEPTOR IN B LYPHOCYTES,M100,1,0
1,0,0,-3.3,0,0,hsa05224,Breast cancer,M100,1,0
1,0,0,-2.6,0,0,GO:0061351,neural precursor cell proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0061298,retina vasculature development in camera-type eye,M100,1,0
1,0,0,-2,0,0,GO:0042026,protein refolding,M100,1,0
0,1,0,0,-2.1,0,GO:0045620,negative regulation of lymphocyte differentiation,M010,1,0
1,0,0,-2.4,0,0,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
0,1,0,0,-2.3,0,GO:0048701,embryonic cranial skeleton morphogenesis,M010,1,0
1,0,0,-2.5,0,0,GO:0043010,camera-type eye development,M100,1,0
0,1,0,0,-2.4,0,GO:1901699,cellular response to nitrogen compound,M010,1,0
1,0,0,-3.1,0,0,GO:0030217,T cell differentiation,M100,1,0
1,0,0,-2.9,0,0,GO:0034616,response to laminar fluid shear stress,M100,1,0
1,0,0,-2,0,0,GO:0046578,regulation of Ras protein signal transduction,M100,1,0
1,0,0,-2.2,0,0,GO:0044409,entry into host,M100,1,0
1,0,0,-4.9,0,0,GO:0072102,glomerulus morphogenesis,M100,1,0
1,0,0,-4.1,0,0,GO:0046651,lymphocyte proliferation,M100,1,0
1,0,0,-3.4,0,0,GO:0045669,positive regulation of osteoblast differentiation,M100,1,0
0,0,1,0,0,-2.1,GO:0002687,positive regulation of leukocyte migration,M001,1,0
1,0,0,-2.1,0,0,GO:0071901,negative regulation of protein serine/threonine kinase activity,M100,1,0
1,0,0,-2,0,0,GO:0034381,plasma lipoprotein particle clearance,M100,1,0
1,0,0,-7.1,0,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M100,1,0
1,0,0,-3.3,0,0,GO:0009615,response to virus,M100,1,0
1,0,0,-2.6,0,0,GO:0000302,response to reactive oxygen species,M100,1,0
0,1,0,0,-2.4,0,GO:0046636,negative regulation of alpha-beta T cell activation,M010,1,0
1,0,0,-2.1,0,0,GO:0010972,negative regulation of G2/M transition of mitotic cell cycle,M100,1,0
1,0,0,-2.4,0,0,GO:0051604,protein maturation,M100,1,0
0,0,1,0,0,-4.1,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M001,1,0
0,0,1,0,0,-3.4,GO:0002366,leukocyte activation involved in immune response,M001,1,0
1,0,0,-2.9,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.7,0,0,WP4262,Breast cancer pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0060348,bone development,M100,1,0
1,0,0,-2.2,0,0,GO:0042069,regulation of catecholamine metabolic process,M100,1,0
0,0,1,0,0,-2.2,GO:0006633,fatty acid biosynthetic process,M001,1,0
1,0,0,-3.3,0,0,GO:0010001,glial cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0097006,regulation of plasma lipoprotein particle levels,M100,1,0
1,0,0,-4,0,0,R-HSA-168898,Toll-like Receptor Cascades,M100,1,0
0,0,1,0,0,-3.1,GO:0038093,Fc receptor signaling pathway,M001,1,0
0,0,1,0,0,-3.3,GO:0071715,icosanoid transport,M001,1,0
1,0,0,-3.1,0,0,GO:0010632,regulation of epithelial cell migration,M100,1,0
0,1,0,0,-3.1,0,R-HSA-9027284,Erythropoietin activates RAS,M010,1,0
1,0,0,-3.9,0,0,GO:0060099,"regulation of phagocytosis, engulfment",M100,1,0
1,0,0,-4.1,0,0,GO:0061438,renal system vasculature morphogenesis,M100,1,0
1,0,0,-3.4,0,0,WP2583,T cell receptor and co stimulatory signaling,M100,1,0
1,0,0,-2.1,0,0,hsa05323,Rheumatoid arthritis,M100,1,0
1,0,0,-2.8,0,0,hsa04151,PI3K-Akt signaling pathway,M100,1,0
1,0,0,-2.9,0,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M100,1,0
0,0,1,0,0,-2.2,R-HSA-5621481,C-type lectin receptors (CLRs),M001,1,0
1,0,0,-2.6,0,0,M79,PID TRAIL PATHWAY,M100,1,0
1,0,0,-2.1,0,0,WP5224,2q37 copy number variation syndrome,M100,1,0
1,0,0,-2.3,0,0,WP5036,Angiotensin II receptor type 1 pathway,M100,1,0
1,0,0,-3.9,0,0,GO:0035303,regulation of dephosphorylation,M100,1,0
1,0,0,-3.2,0,0,WP3298,Melatonin metabolism and effects,M100,1,0
0,0,1,0,0,-5.6,hsa04666,Fc gamma R-mediated phagocytosis,M001,1,0
1,0,0,-3.4,0,0,hsa04145,Phagosome,M100,1,0
0,1,0,0,-2.4,0,GO:1990858,cellular response to lectin,M010,1,0
1,0,0,-2.7,0,0,GO:0070339,response to bacterial lipopeptide,M100,1,0
1,0,0,-3.2,0,0,GO:0016032,viral process,M100,1,0
1,0,0,-3.5,0,0,GO:0050679,positive regulation of epithelial cell proliferation,M100,1,0
0,0,1,0,0,-2.2,R-HSA-2142753,Arachidonic acid metabolism,M001,1,0
1,0,0,-3.4,0,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M100,1,0
1,0,0,-2.2,0,0,GO:0006957,"complement activation, alternative pathway",M100,1,0
1,0,0,-2.1,0,0,GO:0032872,regulation of stress-activated MAPK cascade,M100,1,0
1,0,0,-2.6,0,0,R-HSA-8980692,RHOA GTPase cycle,M100,1,0
1,0,0,-2.1,0,0,hsa04060,Cytokine-cytokine receptor interaction,M100,1,0
1,0,0,-2.5,0,0,CORUM:313,Cell cycle kinase complex CDK5,M100,1,0
1,0,0,-3,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.7,0,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M100,1,0
1,0,0,-2,0,0,GO:0006839,mitochondrial transport,M100,1,0
0,1,0,0,-2.6,0,GO:2001243,negative regulation of intrinsic apoptotic signaling pathway,M010,1,0
1,0,0,-2.1,0,0,M169,PID INTEGRIN2 PATHWAY,M100,1,0
0,1,0,0,-2.4,0,GO:0060872,semicircular canal development,M010,1,0
1,0,0,-2.5,0,0,GO:0007405,neuroblast proliferation,M100,1,0
1,0,0,-2.5,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
1,0,0,-2.1,0,0,GO:0032371,regulation of sterol transport,M100,1,0
1,0,0,-2.2,0,0,GO:0051701,biological process involved in interaction with host,M100,1,0
0,0,1,0,0,-2.1,GO:0034110,regulation of homotypic cell-cell adhesion,M001,1,0
1,0,0,-2.3,0,0,WP4787,Osteoblast differentiation and related diseases,M100,1,0
0,0,1,0,0,-3.2,GO:0030593,neutrophil chemotaxis,M001,1,0
1,0,0,-3,0,0,GO:0043549,regulation of kinase activity,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9662361,Sensory processing of sound by outer hair cells of the cochlea,M100,1,0
1,0,0,-2.9,0,0,GO:0030832,regulation of actin filament length,M100,1,0
1,0,0,-2.8,0,0,GO:0002711,positive regulation of T cell mediated immunity,M100,1,0
1,0,0,-5.4,0,0,GO:0070661,leukocyte proliferation,M100,1,0
1,0,0,-2.8,0,0,hsa05146,Amoebiasis,M100,1,0
0,0,1,0,0,-2.6,GO:0018212,peptidyl-tyrosine modification,M001,1,0
1,0,0,-4.4,0,0,GO:0002699,positive regulation of immune effector process,M100,1,0
1,0,0,-4.3,0,0,WP4540,Hippo signaling regulation pathways,M100,1,0
1,0,0,-3.4,0,0,GO:0032496,response to lipopolysaccharide,M100,1,0
0,0,1,0,0,-2.3,GO:1990849,vacuolar localization,M001,1,0
1,0,0,-2.7,0,0,R-HSA-9031628,NGF-stimulated transcription,M100,1,0
1,0,0,-3.7,0,0,hsa04810,Regulation of actin cytoskeleton,M100,1,0
0,0,1,0,0,-3.5,R-HSA-76009,Platelet Aggregation (Plug Formation),M001,1,0
1,0,0,-5.5,0,0,hsa05166,Human T-cell leukemia virus 1 infection,M100,1,0
1,0,0,-2.1,0,0,GO:0032374,regulation of cholesterol transport,M100,1,0
1,0,0,-3.4,0,0,R-HSA-73887,Death Receptor Signaling,M100,1,0
1,0,0,-2.4,0,0,GO:1902692,regulation of neuroblast proliferation,M100,1,0
1,0,0,-4.6,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M100,1,0
0,0,1,0,0,-2.9,GO:0043547,positive regulation of GTPase activity,M001,1,0
1,0,0,-2.1,0,0,GO:0032755,positive regulation of interleukin-6 production,M100,1,0
1,0,0,-3.2,0,0,WP545,Complement activation,M100,1,0
1,0,0,-2.6,0,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M100,1,0
0,1,0,0,-2.4,0,GO:1902176,negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,M010,1,0
0,0,1,0,0,-3,R-HSA-9748784,Drug ADME,M001,1,0
1,0,0,-3.3,0,0,GO:0032760,positive regulation of tumor necrosis factor production,M100,1,0
1,0,0,-3,0,0,GO:0014911,positive regulation of smooth muscle cell migration,M100,1,0
1,0,0,-4.4,0,0,GO:0043410,positive regulation of MAPK cascade,M100,1,0
0,1,0,0,-2.5,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M010,1,0
0,0,1,0,0,-3.1,GO:0002532,production of molecular mediator involved in inflammatory response,M001,1,0
1,0,0,-4.1,0,0,M195,PID CMYB PATHWAY,M100,1,0
0,1,0,0,-2.5,0,GO:0031343,positive regulation of cell killing,M010,1,0
1,0,0,-3.8,0,0,GO:0009896,positive regulation of catabolic process,M100,1,0
1,0,0,-3.7,0,0,WP2864,Apoptosis related network due to altered Notch3 in ovarian cancer,M100,1,0
1,0,0,-2.4,0,0,GO:0042326,negative regulation of phosphorylation,M100,1,0
1,0,0,-5.5,0,0,GO:0035239,tube morphogenesis,M100,1,0
1,0,0,-2.5,0,0,R-HSA-5673001,RAF/MAP kinase cascade,M100,1,0
0,0,1,0,0,-2.4,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M001,1,0
1,0,0,-2.2,0,0,GO:0031589,cell-substrate adhesion,M100,1,0
0,0,1,0,0,-2.3,GO:0031663,lipopolysaccharide-mediated signaling pathway,M001,1,0
1,0,0,-3.3,0,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M100,1,0
1,0,0,-3.2,0,0,M226,PID VEGFR1 PATHWAY,M100,1,0
1,0,0,-2.8,0,0,GO:0051051,negative regulation of transport,M100,1,0
0,0,1,0,0,-2.2,GO:0034103,regulation of tissue remodeling,M001,1,0
1,0,0,-4.2,0,0,GO:0030036,actin cytoskeleton organization,M100,1,0
1,0,0,-3.3,0,0,WP4149,White fat cell differentiation,M100,1,0
0,0,1,0,0,-2.9,R-HSA-9006335,Signaling by Erythropoietin,M001,1,0
1,0,0,-2,0,0,GO:2000736,regulation of stem cell differentiation,M100,1,0
1,0,0,-4.4,0,0,GO:0038084,vascular endothelial growth factor signaling pathway,M100,1,0
1,0,0,-5.7,0,0,GO:0042129,regulation of T cell proliferation,M100,1,0
1,0,0,-3.4,0,0,GO:0010810,regulation of cell-substrate adhesion,M100,1,0
1,0,0,-2.8,0,0,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M100,1,0
0,0,1,0,0,-2.2,GO:0090330,regulation of platelet aggregation,M001,1,0
1,0,0,-3,0,0,GO:0048469,cell maturation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-912526,Interleukin receptor SHC signaling,M100,1,0
0,1,0,0,-2,0,GO:0032868,response to insulin,M010,1,0
1,0,0,-2.8,0,0,GO:0097435,supramolecular fiber organization,M100,1,0
1,0,0,-2.4,0,0,M237,PID VEGFR1 2 PATHWAY,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9007101,Rab regulation of trafficking,M100,1,0
1,0,0,-2.1,0,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M100,1,0
0,0,1,0,0,-3.7,GO:0033628,regulation of cell adhesion mediated by integrin,M001,1,0
1,0,0,-3.2,0,0,GO:0002076,osteoblast development,M100,1,0
1,0,0,-2.3,0,0,GO:0044000,movement in host,M100,1,0
1,0,0,-2.4,0,0,R-HSA-194138,Signaling by VEGF,M100,1,0
1,0,0,-2.2,0,0,GO:0016242,negative regulation of macroautophagy,M100,1,0
1,0,0,-2,0,0,GO:0070302,regulation of stress-activated protein kinase signaling cascade,M100,1,0
1,0,0,-2.4,0,0,WP3941,Oxidative damage response,M100,1,0
1,0,0,-2.5,0,0,GO:0051090,regulation of DNA-binding transcription factor activity,M100,1,0
1,0,0,-2.1,0,0,GO:0002714,positive regulation of B cell mediated immunity,M100,1,0
0,0,1,0,0,-2.6,GO:0018108,peptidyl-tyrosine phosphorylation,M001,1,0
1,0,0,-2.3,0,0,GO:0062042,regulation of cardiac epithelial to mesenchymal transition,M100,1,0
1,0,0,-3.2,0,0,WP5322,CKAP4 signaling pathway map,M100,1,0
1,0,0,-2.3,0,0,GO:0045589,regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-2.6,0,0,GO:0001570,vasculogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0061036,positive regulation of cartilage development,M100,1,0
0,1,0,0,-3.1,0,GO:0046639,negative regulation of alpha-beta T cell differentiation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-166520,Signaling by NTRKs,M100,1,0
1,0,0,-2.5,0,0,hsa05322,Systemic lupus erythematosus,M100,1,0
0,0,1,0,0,-2.8,GO:0006650,glycerophospholipid metabolic process,M001,1,0
0,1,0,0,-2,0,WP2018,RANKL RANK signaling pathway,M010,1,0
1,0,0,-2.2,0,0,GO:0010634,positive regulation of epithelial cell migration,M100,1,0
1,0,0,-2.7,0,0,GO:0051044,positive regulation of membrane protein ectodomain proteolysis,M100,1,0
1,0,0,-3,0,0,hsa05211,Renal cell carcinoma,M100,1,0
1,0,0,-2.8,0,0,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M100,1,0
0,1,0,0,-2,0,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M010,1,0
1,0,0,-7.3,0,0,GO:0042327,positive regulation of phosphorylation,M100,1,0
0,1,0,0,-2.1,0,hsa04726,Serotonergic synapse,M010,1,0
1,0,0,-2.2,0,0,GO:0022604,regulation of cell morphogenesis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-373080,Class B/2 (Secretin family receptors),M100,1,0
1,0,0,-2.5,0,0,GO:0097398,cellular response to interleukin-17,M100,1,0
0,1,0,0,-2.2,0,GO:1903320,regulation of protein modification by small protein conjugation or removal,M010,1,0
0,0,1,0,0,-4.4,GO:0050900,leukocyte migration,M001,1,0
1,0,0,-3.8,0,0,GO:0010563,negative regulation of phosphorus metabolic process,M100,1,0
0,0,1,0,0,-2,GO:0007229,integrin-mediated signaling pathway,M001,1,0
1,0,0,-2.4,0,0,hsa05214,Glioma,M100,1,0
1,0,0,-3.2,0,0,GO:1905155,positive regulation of membrane invagination,M100,1,0
0,1,0,0,-2.5,0,hsa04915,Estrogen signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0045807,positive regulation of endocytosis,M100,1,0
1,0,0,-2.5,0,0,CORUM:2383,ITGA5-ITGB1-FN1-TGM2 complex,M100,1,0
1,0,0,-3.3,0,0,GO:0150062,complement-mediated synapse pruning,M100,1,0
1,0,0,-2.3,0,0,GO:0001654,eye development,M100,1,0
1,0,0,-3,0,0,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M100,1,0
1,0,0,-3.6,0,0,GO:0032680,regulation of tumor necrosis factor production,M100,1,0
1,0,0,-3.9,0,0,GO:1905153,regulation of membrane invagination,M100,1,0
1,0,0,-4.9,0,0,hsa05162,Measles,M100,1,0
1,0,0,-2.5,0,0,GO:0002519,natural killer cell tolerance induction,M100,1,0
1,0,0,-3.8,0,0,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M100,1,0
1,0,0,-2.4,0,0,GO:0043124,negative regulation of canonical NF-kappaB signal transduction,M100,1,0
1,0,0,-2,0,0,R-HSA-373755,Semaphorin interactions,M100,1,0
0,1,0,0,-3.2,0,GO:0060021,roof of mouth development,M010,1,0
1,0,0,-3.6,0,0,WP4263,Pancreatic adenocarcinoma pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0043409,negative regulation of MAPK cascade,M100,1,0
1,0,0,-2.4,0,0,hsa05226,Gastric cancer,M100,1,0
0,1,0,0,-2.4,0,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M010,1,0
1,0,0,-2.8,0,0,WP254,Apoptosis,M100,1,0
1,0,0,-2.1,0,0,GO:0032689,negative regulation of type II interferon production,M100,1,0
1,0,0,-2.2,0,0,WP4290,Metabolic reprogramming in colon cancer,M100,1,0
1,0,0,-3.8,0,0,GO:0097028,dendritic cell differentiation,M100,1,0
1,0,0,-3.6,0,0,WP3851,TLR4 signaling and tolerance,M100,1,0
1,0,0,-2.9,0,0,GO:0072310,glomerular epithelial cell development,M100,1,0
1,0,0,-2.3,0,0,hsa05321,Inflammatory bowel disease,M100,1,0
1,0,0,-2.2,0,0,GO:2000668,regulation of dendritic cell apoptotic process,M100,1,0
0,0,1,0,0,-2.3,GO:0032418,lysosome localization,M001,1,0
0,0,1,0,0,-3.5,GO:0030595,leukocyte chemotaxis,M001,1,0
0,1,0,0,-2.1,0,CORUM:642,CtBP complex,M010,1,0
1,0,0,-3.6,0,0,GO:0043405,regulation of MAP kinase activity,M100,1,0
1,0,0,-2.1,0,0,GO:0002455,humoral immune response mediated by circulating immunoglobulin,M100,1,0
1,0,0,-3.9,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:1900015,regulation of cytokine production involved in inflammatory response,M100,1,0
1,0,0,-2.6,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-3.7,0,0,GO:0030890,positive regulation of B cell proliferation,M100,1,0
1,0,0,-2.3,0,0,GO:0007173,epidermal growth factor receptor signaling pathway,M100,1,0
1,0,0,-2.9,0,0,WP5402,10q22q23 copy number variation,M100,1,0
0,0,1,0,0,-2.2,GO:0032507,maintenance of protein location in cell,M001,1,0
1,0,0,-4,0,0,WP4541,Hippo Merlin signaling dysregulation,M100,1,0
1,0,0,-3.9,0,0,hsa05171,Coronavirus disease - COVID-19,M100,1,0
1,0,0,-3.1,0,0,GO:0071222,cellular response to lipopolysaccharide,M100,1,0
0,1,0,0,-2.5,0,GO:0045581,negative regulation of T cell differentiation,M010,1,0
1,0,0,-2.1,0,0,GO:0071241,cellular response to inorganic substance,M100,1,0
1,0,0,-2.5,0,0,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M100,1,0
1,0,0,-3.1,0,0,GO:0030879,mammary gland development,M100,1,0
1,0,0,-2.1,0,0,GO:1901653,cellular response to peptide,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9020956,Interleukin-27 signaling,M100,1,0
0,1,0,0,-2.2,0,M206,PID PDGFRA PATHWAY,M010,1,0
0,1,0,0,-2.1,0,GO:0048704,embryonic skeletal system morphogenesis,M010,1,0
1,0,0,-3.5,0,0,WP4666,Hepatitis B infection,M100,1,0
1,0,0,-4.6,0,0,WP3888,VEGFA VEGFR2 signaling,M100,1,0
0,0,1,0,0,-2.5,GO:0090407,organophosphate biosynthetic process,M001,1,0
0,1,0,0,-3.4,0,M122,PID IL2 1PATHWAY,M010,1,0
1,0,0,-3.9,0,0,hsa05165,Human papillomavirus infection,M100,1,0
1,0,0,-2.5,0,0,GO:0014032,neural crest cell development,M100,1,0
1,0,0,-3.3,0,0,GO:0098586,cellular response to virus,M100,1,0
1,0,0,-2.6,0,0,GO:0050848,regulation of calcium-mediated signaling,M100,1,0
1,0,0,-3,0,0,GO:0048708,astrocyte differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0048008,platelet-derived growth factor receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,R-HSA-166658,Complement cascade,M100,1,0
1,0,0,-2.8,0,0,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M100,1,0
1,0,0,-2.3,0,0,GO:1901652,response to peptide,M100,1,0
0,1,0,0,-3.9,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M010,1,0
0,1,0,0,-2.2,0,hsa04072,Phospholipase D signaling pathway,M010,1,0
1,0,0,-3.9,0,0,GO:0032675,regulation of interleukin-6 production,M100,1,0
1,0,0,-2.1,0,0,GO:0070849,response to epidermal growth factor,M100,1,0
1,0,0,-3,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-2.1,0,0,WP4585,Cancer immunotherapy by PD 1 blockade,M100,1,0
0,0,1,0,0,-2.8,GO:0033559,unsaturated fatty acid metabolic process,M001,1,0
1,0,0,-2.7,0,0,GO:0032808,lacrimal gland development,M100,1,0
1,0,0,-4.9,0,0,WP4659,Gastrin signaling pathway,M100,1,0
1,0,0,-3,0,0,hsa05134,Legionellosis,M100,1,0
1,0,0,-2.7,0,0,GO:0042063,gliogenesis,M100,1,0
0,0,1,0,0,-2.5,GO:0002279,mast cell activation involved in immune response,M001,1,0
0,0,1,0,0,-2.4,GO:0060491,regulation of cell projection assembly,M001,1,0
1,0,0,-3.8,0,0,GO:0035306,positive regulation of dephosphorylation,M100,1,0
1,0,0,-2.5,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M100,1,0
1,0,0,-3.6,0,0,GO:0032945,negative regulation of mononuclear cell proliferation,M100,1,0
0,1,0,0,-3.7,0,R-HSA-4086398,Ca2+ pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0006935,chemotaxis,M100,1,0
1,0,0,-4.1,0,0,GO:0051347,positive regulation of transferase activity,M100,1,0
1,0,0,-4.4,0,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M100,1,0
1,0,0,-2.7,0,0,GO:0070528,protein kinase C signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0048844,artery morphogenesis,M100,1,0
1,0,0,-2.2,0,0,M201,PID ERBB NETWORK PATHWAY,M100,1,0
0,0,1,0,0,-2.5,WP5321,Prostaglandin and leukotriene metabolism in senescence,M001,1,0
1,0,0,-3.6,0,0,WP4018,Clear cell renal cell carcinoma pathways,M100,1,0
1,0,0,-2.2,0,0,GO:0090383,phagosome acidification,M100,1,0
1,0,0,-2.4,0,0,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M100,1,0
1,0,0,-3.1,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-2.4,0,0,hsa04940,Type I diabetes mellitus,M100,1,0
1,0,0,-2.6,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M100,1,0
0,0,1,0,0,-3,GO:0045577,regulation of B cell differentiation,M001,1,0
1,0,0,-2.7,0,0,GO:2001188,regulation of T cell activation via T cell receptor contact with antigen bound to MHC molecule on antigen presenting cell,M100,1,0
1,0,0,-2.9,0,0,WP5382,TGF Smad signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0034121,regulation of toll-like receptor signaling pathway,M100,1,0
1,0,0,-2,0,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0007160,cell-matrix adhesion,M100,1,0
1,0,0,-4.3,0,0,GO:0006898,receptor-mediated endocytosis,M100,1,0
1,0,0,-2.2,0,0,M137,PID VEGF VEGFR PATHWAY,M100,1,0
1,0,0,-2.2,0,0,GO:0034377,plasma lipoprotein particle assembly,M100,1,0
1,0,0,-2.1,0,0,GO:0002526,acute inflammatory response,M100,1,0
0,0,1,0,0,-3.3,GO:0018904,ether metabolic process,M001,1,0
1,0,0,-2.6,0,0,WP306,Focal adhesion,M100,1,0
1,0,0,-3,0,0,hsa04510,Focal adhesion,M100,1,0
1,0,0,-2.4,0,0,WP2324,AGE RAGE pathway,M100,1,0
1,0,0,-2.7,0,0,WP4674,Head and neck squamous cell carcinoma,M100,1,0
1,0,0,-3.3,0,0,WP395,IL 4 signaling pathway,M100,1,0
1,0,0,-6,0,0,GO:0001525,angiogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0097530,granulocyte migration,M001,1,0
1,0,0,-2.1,0,0,GO:2000573,positive regulation of DNA biosynthetic process,M100,1,0
0,1,0,0,-3.2,0,GO:0015914,phospholipid transport,M010,1,0
1,0,0,-2.5,0,0,CORUM:1519,IL6ST-PRKCD-STAT3 complex,M100,1,0
0,1,0,0,-2.4,0,GO:1990840,response to lectin,M010,1,0
1,0,0,-3.3,0,0,M91,PID TCPTP PATHWAY,M100,1,0
1,0,0,-2.3,0,0,R-HSA-909733,Interferon alpha/beta signaling,M100,1,0
1,0,0,-2.1,0,0,GO:0002888,positive regulation of myeloid leukocyte mediated immunity,M100,1,0
1,0,0,-5.1,0,0,GO:0045667,regulation of osteoblast differentiation,M100,1,0
1,0,0,-3.7,0,0,GO:0060759,regulation of response to cytokine stimulus,M100,1,0
1,0,0,-3.6,0,0,GO:0043123,positive regulation of canonical NF-kappaB signal transduction,M100,1,0
0,1,0,0,-2.4,0,GO:0072089,stem cell proliferation,M010,1,0
1,0,0,-2.1,0,0,GO:0032743,positive regulation of interleukin-2 production,M100,1,0
1,0,0,-2.6,0,0,GO:0009409,response to cold,M100,1,0
0,0,1,0,0,-3.2,GO:0002688,regulation of leukocyte chemotaxis,M001,1,0
1,0,0,-2.3,0,0,GO:0042176,regulation of protein catabolic process,M100,1,0
1,0,0,-2.1,0,0,hsa05220,Chronic myeloid leukemia,M100,1,0
1,0,0,-2.6,0,0,hsa01522,Endocrine resistance,M100,1,0
1,0,0,-2.1,0,0,M254,PID MYC REPRESS PATHWAY,M100,1,0
1,0,0,-2.5,0,0,CORUM:6418,C1q complex,M100,1,0
1,0,0,-3.8,0,0,GO:0031342,negative regulation of cell killing,M100,1,0
1,0,0,-2.5,0,0,GO:0043301,negative regulation of leukocyte degranulation,M100,1,0
1,0,0,-4,0,0,GO:0071219,cellular response to molecule of bacterial origin,M100,1,0
1,0,0,-3.6,0,0,GO:0035924,cellular response to vascular endothelial growth factor stimulus,M100,1,0
1,0,0,-3.1,0,0,GO:0070372,regulation of ERK1 and ERK2 cascade,M100,1,0
0,1,0,0,-2.1,0,GO:0071375,cellular response to peptide hormone stimulus,M010,1,0
0,0,1,0,0,-4.2,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M001,1,0
0,1,0,0,-2.4,0,M268,PID S1P S1P2 PATHWAY,M010,1,0
1,0,0,-2.5,0,0,GO:0038086,VEGF-activated platelet-derived growth factor receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,hsa05340,Primary immunodeficiency,M100,1,0
0,0,1,0,0,-2.7,M210,PID IL8 CXCR2 PATHWAY,M001,1,0
1,0,0,-2.9,0,0,WP4172,PI3K Akt signaling pathway,M100,1,0
1,0,0,-3.5,0,0,hsa05164,Influenza A,M100,1,0
1,0,0,-2.9,0,0,GO:0002064,epithelial cell development,M100,1,0
0,0,1,0,0,-2.7,GO:0019369,arachidonic acid metabolic process,M001,1,0
1,0,0,-4.1,0,0,GO:0002821,positive regulation of adaptive immune response,M100,1,0
1,0,0,-2.2,0,0,hsa05416,Viral myocarditis,M100,1,0
1,0,0,-2.4,0,0,GO:0002088,lens development in camera-type eye,M100,1,0
1,0,0,-3.2,0,0,GO:0034330,cell junction organization,M100,1,0
1,0,0,-2,0,0,GO:0060070,canonical Wnt signaling pathway,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9700206,Signaling by ALK in cancer,M100,1,0
0,0,1,0,0,-4.4,GO:1901503,ether biosynthetic process,M001,1,0
1,0,0,-2.7,0,0,GO:0002720,positive regulation of cytokine production involved in immune response,M100,1,0
1,0,0,-3.8,0,0,GO:0030029,actin filament-based process,M100,1,0
1,0,0,-6.9,0,0,GO:0001934,positive regulation of protein phosphorylation,M100,1,0
1,0,0,-4,0,0,GO:0045860,positive regulation of protein kinase activity,M100,1,0
1,0,0,-2.8,0,0,GO:0002702,positive regulation of production of molecular mediator of immune response,M100,1,0
0,1,0,0,-2,0,GO:1902106,negative regulation of leukocyte differentiation,M010,1,0
1,0,0,-2.7,0,0,hsa05131,Shigellosis,M100,1,0
0,0,1,0,0,-2.4,GO:0010543,regulation of platelet activation,M001,1,0
0,1,0,0,-2.4,0,GO:0097094,craniofacial suture morphogenesis,M010,1,0
1,0,0,-4.2,0,0,WP1772,Apoptosis modulation and signaling,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5213460,RIPK1-mediated regulated necrosis,M100,1,0
1,0,0,-2,0,0,GO:0010633,negative regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.8,0,M190,PID TCR JNK PATHWAY,M010,1,0
0,1,0,0,-2.4,0,GO:0016482,cytosolic transport,M010,1,0
1,0,0,-2.5,0,0,GO:1903317,regulation of protein maturation,M100,1,0
1,0,0,-2.7,0,0,hsa05230,Central carbon metabolism in cancer,M100,1,0
0,0,1,0,0,-2.9,GO:1990266,neutrophil migration,M001,1,0
1,0,0,-2.8,0,0,M166,PID ATF2 PATHWAY,M100,1,0
1,0,0,-2.9,0,0,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M100,1,0
1,0,0,-2.3,0,0,R-HSA-6811558,"PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling",M100,1,0
1,0,0,-5.1,0,0,M174,PID UPA UPAR PATHWAY,M100,1,0
1,0,0,-3,0,0,GO:0035304,regulation of protein dephosphorylation,M100,1,0
1,0,0,-2.1,0,0,GO:0002052,positive regulation of neuroblast proliferation,M100,1,0
1,0,0,-2,0,0,GO:0048821,erythrocyte development,M100,1,0
1,0,0,-2.3,0,0,R-HSA-416482,G alpha (12/13) signalling events,M100,1,0
0,1,0,0,-2.5,0,WP127,IL 5 signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0010718,positive regulation of epithelial to mesenchymal transition,M100,1,0
1,0,0,-2.5,0,0,CORUM:5269,TNF-alpha/NF-kappa B signaling complex 8,M100,1,0
0,1,0,0,-2.1,0,GO:0009595,detection of biotic stimulus,M010,1,0
0,1,0,0,-3,0,GO:0098581,detection of external biotic stimulus,M010,1,0
1,0,0,-3.3,0,0,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-3,0,0,GO:2000146,negative regulation of cell motility,M100,1,0
0,1,0,0,-2.4,0,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M010,1,0
0,1,0,0,-2.2,0,GO:0150077,regulation of neuroinflammatory response,M010,1,0
1,0,0,-3.4,0,0,GO:0072015,podocyte development,M100,1,0
1,0,0,-4.7,0,0,WP4630,Measles virus infection,M100,1,0
1,0,0,-2.9,0,0,R-HSA-9694516,SARS-CoV-2 Infection,M100,1,0
0,0,1,0,0,-2.3,R-HSA-6802952,Signaling by BRAF and RAF1 fusions,M001,1,0
1,0,0,-3.7,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-5,0,0,hsa01521,EGFR tyrosine kinase inhibitor resistance,M100,1,0
1,0,0,-5.5,0,0,GO:0140747,regulation of ncRNA transcription,M100,1,0
0,0,1,0,0,-2.4,GO:0002448,mast cell mediated immunity,M001,1,0
0,1,0,0,-2,0,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M010,1,0
1,0,0,-7.4,0,0,GO:0050670,regulation of lymphocyte proliferation,M100,1,0
1,0,0,-2.8,0,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M100,1,0
1,0,0,-2,0,0,GO:0002501,peptide antigen assembly with MHC protein complex,M100,1,0
1,0,0,-2.6,0,0,GO:0090130,tissue migration,M100,1,0
1,0,0,-2.1,0,0,GO:0045599,negative regulation of fat cell differentiation,M100,1,0
1,0,0,-5.5,0,0,GO:0045766,positive regulation of angiogenesis,M100,1,0
0,1,0,0,-2.8,0,GO:0003223,ventricular compact myocardium morphogenesis,M010,1,0
0,1,0,0,-2.5,0,WP363,Wnt signaling pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0050672,negative regulation of lymphocyte proliferation,M100,1,0
1,0,0,-2.8,0,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M100,1,0
1,0,0,-3.6,0,0,GO:0031623,receptor internalization,M100,1,0
1,0,0,-3,0,0,WP3617,Photodynamic therapy induced NF kB survival signaling,M100,1,0
1,0,0,-3.4,0,0,GO:0002704,negative regulation of leukocyte mediated immunity,M100,1,0
1,0,0,-5.1,0,0,GO:0002706,regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-3.2,0,0,GO:0060249,anatomical structure homeostasis,M100,1,0
1,0,0,-3,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.4,0,0,GO:0071364,cellular response to epidermal growth factor stimulus,M100,1,0
1,0,0,-2.4,0,0,GO:0010883,regulation of lipid storage,M100,1,0
1,0,0,-2.2,0,0,GO:0051607,defense response to virus,M100,1,0
0,1,0,0,-2.4,0,WP3877,MYD88 distinct input output pathway,M010,1,0
1,0,0,-2.8,0,0,M65,PID FRA PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0014033,neural crest cell differentiation,M100,1,0
1,0,0,-5.7,0,0,GO:0001944,vasculature development,M100,1,0
1,0,0,-3,0,0,GO:1903035,negative regulation of response to wounding,M100,1,0
0,1,0,0,-2.1,0,GO:1903053,regulation of extracellular matrix organization,M010,1,0
1,0,0,-3.3,0,0,GO:0072104,glomerular capillary formation,M100,1,0
1,0,0,-3.3,0,0,GO:0060978,angiogenesis involved in coronary vascular morphogenesis,M100,1,0
1,0,0,-4.1,0,0,GO:0050921,positive regulation of chemotaxis,M100,1,0
1,0,0,-5.8,0,0,GO:1902893,regulation of miRNA transcription,M100,1,0
1,0,0,-4.1,0,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.1,0,0,GO:0031400,negative regulation of protein modification process,M100,1,0
1,0,0,-3.9,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
1,0,0,-2.7,0,0,GO:0002922,positive regulation of humoral immune response,M100,1,0
0,1,0,0,-2.1,0,GO:1902993,positive regulation of amyloid precursor protein catabolic process,M010,1,0
0,0,1,0,0,-2.1,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M001,1,0
1,0,0,-2.1,0,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M100,1,0
0,1,0,0,-2.8,0,GO:0017121,plasma membrane phospholipid scrambling,M010,1,0
1,0,0,-2.5,0,0,R-HSA-202424,Downstream TCR signaling,M100,1,0
0,1,0,0,-2,0,R-HSA-6783783,Interleukin-10 signaling,M010,1,0
1,0,0,-2.8,0,0,GO:0032729,positive regulation of type II interferon production,M100,1,0
0,0,1,0,0,-3,WP304,Kit receptor signaling pathway,M001,1,0
1,0,0,-2.9,0,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-3.4,0,0,GO:0010811,positive regulation of cell-substrate adhesion,M100,1,0
1,0,0,-2.3,0,0,GO:0033238,regulation of amine metabolic process,M100,1,0
1,0,0,-2,0,0,R-HSA-8878166,Transcriptional regulation by RUNX2,M100,1,0
0,0,1,0,0,-3.3,WP167,Eicosanoid synthesis,M001,1,0
1,0,0,-3.4,0,0,hsa05140,Leishmaniasis,M100,1,0
1,0,0,-4.1,0,0,GO:0001818,negative regulation of cytokine production,M100,1,0
1,0,0,-3.8,0,0,GO:0044092,negative regulation of molecular function,M100,1,0
0,1,0,0,-3.1,0,GO:0006991,response to sterol depletion,M010,1,0
1,0,0,-4.8,0,0,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0010638,positive regulation of organelle organization,M100,1,0
1,0,0,-3.1,0,0,M54,PID IL12 2PATHWAY,M100,1,0
1,0,0,-5.9,0,0,GO:2000630,positive regulation of miRNA metabolic process,M100,1,0
1,0,0,-2,0,0,WP516,Hypertrophy model,M100,1,0
0,0,1,0,0,-2.5,GO:0006636,unsaturated fatty acid biosynthetic process,M001,1,0
1,0,0,-4.4,0,0,GO:0045765,regulation of angiogenesis,M100,1,0
1,0,0,-2.4,0,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M100,1,0
1,0,0,-2.7,0,0,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M100,1,0
1,0,0,-3.6,0,0,hsa04218,Cellular senescence,M100,1,0
1,0,0,-2.9,0,0,GO:0010631,epithelial cell migration,M100,1,0
1,0,0,-2.9,0,0,GO:0035307,positive regulation of protein dephosphorylation,M100,1,0
1,0,0,-6.3,0,0,GO:2000628,regulation of miRNA metabolic process,M100,1,0
0,1,0,0,-2.1,0,GO:0043434,response to peptide hormone,M010,1,0
0,0,1,0,0,-2,hsa04613,Neutrophil extracellular trap formation,M001,1,0
0,1,0,0,-2.2,0,R-HSA-111885,Opioid Signalling,M010,1,0
1,0,0,-2,0,0,M143,PID IL2 PI3K PATHWAY,M100,1,0
0,1,0,0,-2.1,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M010,1,0
1,0,0,-6.6,0,0,GO:0008283,cell population proliferation,M100,1,0
1,0,0,-4.8,0,0,hsa04630,JAK-STAT signaling pathway,M100,1,0
1,0,0,-2.3,0,0,GO:0007015,actin filament organization,M100,1,0
0,1,0,0,-2.1,0,M276,PID FGF PATHWAY,M010,1,0
1,0,0,-2.2,0,0,GO:0042053,regulation of dopamine metabolic process,M100,1,0
0,1,0,0,-2.8,0,R-HSA-1234158,Regulation of gene expression by Hypoxia-inducible Factor,M010,1,0
1,0,0,-4.1,0,0,GO:0061439,kidney vasculature morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0034351,negative regulation of glial cell apoptotic process,M100,1,0
0,1,0,0,-5.2,0,hsa04650,Natural killer cell mediated cytotoxicity,M010,1,0
1,0,0,-2.7,0,0,hsa04612,Antigen processing and presentation,M100,1,0
1,0,0,-4.1,0,0,GO:0032943,mononuclear cell proliferation,M100,1,0
1,0,0,-4.1,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
1,0,0,-2.7,0,0,R-HSA-166786,Creation of C4 and C2 activators,M100,1,0
1,0,0,-2.1,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M100,1,0
1,0,0,-2.7,0,0,WP619,Type II interferon signaling,M100,1,0
0,1,0,0,-2.1,0,GO:1903054,negative regulation of extracellular matrix organization,M010,1,0
1,0,0,-4.3,0,0,GO:0033674,positive regulation of kinase activity,M100,1,0
1,0,0,-2.3,0,0,GO:0007006,mitochondrial membrane organization,M100,1,0
1,0,0,-5.2,0,0,WP5087,Pleural mesothelioma,M100,1,0
0,0,1,0,0,-2.5,GO:0043303,mast cell degranulation,M001,1,0
1,0,0,-2.5,0,0,hsa04217,Necroptosis,M100,1,0
1,0,0,-2.5,0,0,M5493,WNT SIGNALING,M100,1,0
1,0,0,-3.7,0,0,GO:0001954,positive regulation of cell-matrix adhesion,M100,1,0
1,0,0,-2.6,0,0,GO:0071900,regulation of protein serine/threonine kinase activity,M100,1,0
1,0,0,-2.3,0,0,GO:0002430,complement receptor mediated signaling pathway,M100,1,0
1,0,0,-2.1,0,0,M53,PID INTEGRIN3 PATHWAY,M100,1,0
1,0,0,-5.7,0,0,GO:0031401,positive regulation of protein modification process,M100,1,0
1,0,0,-3.2,0,0,R-HSA-1227986,Signaling by ERBB2,M100,1,0
1,0,0,-3.1,0,0,GO:1900744,regulation of p38MAPK cascade,M100,1,0
1,0,0,-3,0,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M100,1,0
1,0,0,-2.2,0,0,GO:0044089,positive regulation of cellular component biogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0032642,regulation of chemokine production,M100,1,0
0,1,0,0,-3.2,0,GO:0031641,regulation of myelination,M010,1,0
1,0,0,-2.2,0,0,R-HSA-199418,Negative regulation of the PI3K/AKT network,M100,1,0
1,0,0,-2.3,0,0,WP4534,Mechanoregulation and pathology of YAP TAZ via Hippo and non Hippo mechanisms,M100,1,0
1,0,0,-2.1,0,0,R-HSA-5602358,Diseases associated with the TLR signaling cascade,M100,1,0
1,0,0,-2.5,0,0,GO:0097396,response to interleukin-17,M100,1,0
0,0,1,0,0,-2.4,M159,PID AMB2 NEUTROPHILS PATHWAY,M001,1,0
1,0,0,-2.8,0,0,GO:0019058,viral life cycle,M100,1,0
0,1,0,0,-2.4,0,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M010,1,0
1,0,0,-3.6,0,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M100,1,0
1,0,0,-2.8,0,0,hsa04640,Hematopoietic cell lineage,M100,1,0
1,0,0,-2.7,0,0,M279,PID RB 1PATHWAY,M100,1,0
1,0,0,-3.2,0,0,GO:0001503,ossification,M100,1,0
0,0,1,0,0,-3,GO:0006887,exocytosis,M001,1,0
1,0,0,-3.3,0,0,GO:0032663,regulation of interleukin-2 production,M100,1,0
1,0,0,-3.8,0,0,GO:0001936,regulation of endothelial cell proliferation,M100,1,0
1,0,0,-3.6,0,0,GO:0033598,mammary gland epithelial cell proliferation,M100,1,0
1,0,0,-2.8,0,0,GO:0038127,ERBB signaling pathway,M100,1,0
1,0,0,-2.7,0,0,GO:0034405,response to fluid shear stress,M100,1,0
1,0,0,-2.3,0,0,GO:0006958,"complement activation, classical pathway",M100,1,0
1,0,0,-2.7,0,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.8,0,0,GO:0090559,regulation of membrane permeability,M100,1,0
1,0,0,-2.8,0,0,WP558,Complement and coagulation cascades,M100,1,0
0,1,0,0,-2.1,0,M23,PID WNT NONCANONICAL PATHWAY,M010,1,0
1,0,0,-2,0,0,GO:1905039,carboxylic acid transmembrane transport,M100,1,0
0,0,1,0,0,-4,GO:0050764,regulation of phagocytosis,M001,1,0
0,0,1,0,0,-2.2,GO:0120031,plasma membrane bounded cell projection assembly,M001,1,0
1,0,0,-2,0,0,GO:0044818,mitotic G2/M transition checkpoint,M100,1,0
1,0,0,-4.9,0,0,hsa05132,Salmonella infection,M100,1,0
1,0,0,-2.7,0,0,GO:0007369,gastrulation,M100,1,0
1,0,0,-2.3,0,0,R-HSA-2424491,DAP12 signaling,M100,1,0
1,0,0,-2.8,0,0,WP4331,Neovascularisation processes,M100,1,0
1,0,0,-2.5,0,0,GO:0001569,branching involved in blood vessel morphogenesis,M100,1,0
1,0,0,-2.5,0,0,hsa04514,Cell adhesion molecules,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9018519,Estrogen-dependent gene expression,M100,1,0
1,0,0,-2.3,0,0,M197,PID HIV NEF PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0071498,cellular response to fluid shear stress,M100,1,0
1,0,0,-2,0,0,GO:0007626,locomotory behavior,M100,1,0
1,0,0,-2.6,0,0,GO:0032722,positive regulation of chemokine production,M100,1,0
1,0,0,-2.1,0,0,R-HSA-5260271,Diseases of Immune System,M100,1,0
1,0,0,-2.7,0,0,GO:0072126,positive regulation of glomerular mesangial cell proliferation,M100,1,0
1,0,0,-2.7,0,0,GO:0010573,vascular endothelial growth factor production,M100,1,0
1,0,0,-2.7,0,0,GO:0071354,cellular response to interleukin-6,M100,1,0
1,0,0,-8.1,0,0,GO:0045937,positive regulation of phosphate metabolic process,M100,1,0
1,0,0,-2.4,0,0,R-HSA-9662360,Sensory processing of sound by inner hair cells of the cochlea,M100,1,0
0,0,1,0,0,-2,GO:0097529,myeloid leukocyte migration,M001,1,0
1,0,0,-5.5,0,0,GO:0045637,regulation of myeloid cell differentiation,M100,1,0
1,0,0,-3.5,0,0,GO:0022408,negative regulation of cell-cell adhesion,M100,1,0
1,0,0,-5.1,0,0,WP4806,EGFR tyrosine kinase inhibitor resistance,M100,1,0
1,0,0,-2.9,0,0,M94,PID FAS PATHWAY,M100,1,0
1,0,0,-2.7,0,0,GO:0071221,cellular response to bacterial lipopeptide,M100,1,0
1,0,0,-2.5,0,0,GO:0060840,artery development,M100,1,0
1,0,0,-2.5,0,0,GO:0048857,neural nucleus development,M100,1,0
1,0,0,-4.3,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
0,1,0,0,-2.6,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M010,1,0
1,0,0,-2.6,0,0,R-HSA-9682385,FLT3 signaling in disease,M100,1,0
1,0,0,-2.7,0,0,GO:2000377,regulation of reactive oxygen species metabolic process,M100,1,0
1,0,0,-3.4,0,0,R-HSA-166663,Initial triggering of complement,M100,1,0
1,0,0,-2.7,0,0,GO:0071220,cellular response to bacterial lipoprotein,M100,1,0
0,0,1,0,0,-2.5,M275,PID ALPHA SYNUCLEIN PATHWAY,M001,1,0
1,0,0,-2.7,0,0,GO:0032493,response to bacterial lipoprotein,M100,1,0
0,1,0,0,-2.5,0,M290,PID IL12 STAT4 PATHWAY,M010,1,0
1,0,0,-2.7,0,0,GO:2000739,regulation of mesenchymal stem cell differentiation,M100,1,0
1,0,0,-3.8,0,0,GO:0006956,complement activation,M100,1,0
1,0,0,-3.2,0,0,GO:0060100,"positive regulation of phagocytosis, engulfment",M100,1,0
1,0,0,-2.2,0,0,WP236,Adipogenesis,M100,1,0
0,0,1,0,0,-2.5,GO:0045017,glycerolipid biosynthetic process,M001,1,0
0,1,0,0,-3,0,R-HSA-392518,Signal amplification,M010,1,0
0,1,0,0,-3.5,0,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M010,1,0
1,0,0,-3.6,0,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M100,1,0
0,0,1,0,0,-2.9,GO:0046474,glycerophospholipid biosynthetic process,M001,1,0
1,0,0,-3.8,0,0,hsa05161,Hepatitis B,M100,1,0
1,0,0,-3,0,0,GO:0008064,regulation of actin polymerization or depolymerization,M100,1,0
1,0,0,-2.1,0,0,M68,PID RHOA REG PATHWAY,M100,1,0
1,0,0,-2.5,0,0,GO:0002381,immunoglobulin production involved in immunoglobulin-mediated immune response,M100,1,0
1,0,0,-2.2,0,0,GO:0140546,defense response to symbiont,M100,1,0
1,0,0,-2.1,0,0,hsa05418,Fluid shear stress and atherosclerosis,M100,1,0
0,1,0,0,-2.6,0,GO:1903052,positive regulation of proteolysis involved in protein catabolic process,M010,1,0
1,0,0,-2.7,0,0,GO:0090382,phagosome maturation,M100,1,0
1,0,0,-2.2,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M100,1,0
0,0,1,0,0,-2.5,M177,PID EPHA FWDPATHWAY,M001,1,0
1,0,0,-2.3,0,0,WP3972,PDGFR beta pathway,M100,1,0
0,1,0,0,-2.5,0,GO:0007202,activation of phospholipase C activity,M010,1,0
1,0,0,-2,0,0,GO:0002396,MHC protein complex assembly,M100,1,0
1,0,0,-3.7,0,0,GO:0061448,connective tissue development,M100,1,0
1,0,0,-3.8,0,0,GO:0002709,regulation of T cell mediated immunity,M100,1,0
1,0,0,-3.6,0,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M100,1,0
0,1,0,0,-2.5,0,R-HSA-1912422,Pre-NOTCH Expression and Processing,M010,1,0
0,0,1,0,0,-2.5,GO:0048259,regulation of receptor-mediated endocytosis,M001,1,0
0,0,1,0,0,-2.1,WP364,IL6 signaling pathway,M001,1,0
1,0,0,-2.6,0,0,WP3981,miRNA regulation of prostate cancer signaling pathways,M100,1,0
1,0,0,-3.8,0,0,GO:0045936,negative regulation of phosphate metabolic process,M100,1,0
1,0,0,-3.4,0,0,GO:0032835,glomerulus development,M100,1,0
1,0,0,-2.3,0,0,GO:0010922,positive regulation of phosphatase activity,M100,1,0
1,0,0,-2.8,0,0,GO:0045648,positive regulation of erythrocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0002891,positive regulation of immunoglobulin mediated immune response,M100,1,0
1,0,0,-2.2,0,0,GO:0048340,paraxial mesoderm morphogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:0046486,glycerolipid metabolic process,M001,1,0
1,0,0,-3.8,0,0,GO:0045646,regulation of erythrocyte differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0001938,positive regulation of endothelial cell proliferation,M100,1,0
0,1,0,0,-2.2,0,GO:1903978,regulation of microglial cell activation,M010,1,0
1,0,0,-2.9,0,0,R-HSA-75158,TRAIL  signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0036120,cellular response to platelet-derived growth factor stimulus,M100,1,0
1,0,0,-3.8,0,0,GO:0040011,locomotion,M100,1,0
0,0,1,0,0,-2.1,GO:0002690,positive regulation of leukocyte chemotaxis,M001,1,0
1,0,0,-2.7,0,0,R-HSA-2219530,Constitutive Signaling by Aberrant PI3K in Cancer,M100,1,0
0,1,0,0,-2.4,0,GO:0045862,positive regulation of proteolysis,M010,1,0
1,0,0,-3.3,0,0,GO:1903589,positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,M100,1,0
1,0,0,-2.6,0,0,M100,PID SHP2 PATHWAY,M100,1,0
1,0,0,-2.1,0,0,WP3995,Prion disease pathway,M100,1,0
1,0,0,-5.8,0,0,GO:0050671,positive regulation of lymphocyte proliferation,M100,1,0
1,0,0,-2.6,0,0,GO:0001933,negative regulation of protein phosphorylation,M100,1,0
1,0,0,-2.1,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-3.5,0,0,GO:0001667,ameboidal-type cell migration,M100,1,0
1,0,0,-2.9,0,0,GO:0071695,anatomical structure maturation,M100,1,0
1,0,0,-2.3,0,0,hsa04622,RIG-I-like receptor signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0046902,regulation of mitochondrial membrane permeability,M100,1,0
0,1,0,0,-2.4,0,GO:2000785,regulation of autophagosome assembly,M010,1,0
1,0,0,-2.7,0,0,hsa05212,Pancreatic cancer,M100,1,0
1,0,0,-2.2,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
1,0,0,-5.2,0,0,hsa05150,Staphylococcus aureus infection,M100,1,0
1,0,0,-4.6,0,0,GO:0048871,multicellular organismal-level homeostasis,M100,1,0
1,0,0,-2.8,0,0,GO:0030865,cortical cytoskeleton organization,M100,1,0
1,0,0,-2.3,0,0,hsa05205,Proteoglycans in cancer,M100,1,0
0,1,0,0,-2.8,0,M63,PID AVB3 OPN PATHWAY,M010,1,0
1,0,0,-3.2,0,0,GO:0032649,regulation of type II interferon production,M100,1,0
0,0,1,0,0,-3.7,R-HSA-354192,Integrin signaling,M001,1,0
0,0,1,0,0,-3.1,GO:0045579,positive regulation of B cell differentiation,M001,1,0
1,0,0,-2,0,0,R-HSA-199991,Membrane Trafficking,M100,1,0
1,0,0,-2.4,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M100,1,0
1,0,0,-3.1,0,0,GO:1903531,negative regulation of secretion by cell,M100,1,0
0,0,1,0,0,-2.9,GO:0097242,amyloid-beta clearance,M001,1,0
1,0,0,-3.7,0,0,R-HSA-9013148,CDC42 GTPase cycle,M100,1,0
0,0,1,0,0,-2.5,GO:0006690,icosanoid metabolic process,M001,1,0
1,0,0,-3.3,0,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M100,1,0
1,0,0,-2.1,0,0,GO:0044403,biological process involved in symbiotic interaction,M100,1,0
1,0,0,-3.5,0,0,GO:0042100,B cell proliferation,M100,1,0
0,1,0,0,-2.1,0,WP400,p38 MAPK signaling pathway,M010,1,0
1,0,0,-2.7,0,0,GO:0070613,regulation of protein processing,M100,1,0
1,0,0,-2.4,0,0,GO:1903047,mitotic cell cycle process,M100,1,0
1,0,0,-3.8,0,0,GO:0046849,bone remodeling,M100,1,0
1,0,0,-2.8,0,0,GO:0032956,regulation of actin cytoskeleton organization,M100,1,0
1,0,0,-3.4,0,0,R-HSA-913531,Interferon Signaling,M100,1,0
0,0,1,0,0,-2.5,R-HSA-9013404,RAC2 GTPase cycle,M001,1,0
0,0,1,0,0,-3.7,GO:0046456,icosanoid biosynthetic process,M001,1,0
0,0,1,0,0,-2.3,GO:0006631,fatty acid metabolic process,M001,1,0
0,0,1,0,0,-2.1,GO:0045124,regulation of bone resorption,M001,1,0
1,0,0,-2.5,0,0,CORUM:5735,TGF-beta receptor-SMAD3 complex,M100,1,0
1,0,0,-3.3,0,0,WP2355,Corticotropin releasing hormone signaling pathway,M100,1,0
1,0,0,-3,0,0,GO:1902903,regulation of supramolecular fiber organization,M100,1,0
0,0,1,0,0,-2.9,GO:0120033,negative regulation of plasma membrane bounded cell projection assembly,M001,1,0
0,0,1,0,0,-2.6,GO:0033630,positive regulation of cell adhesion mediated by integrin,M001,1,0
1,0,0,-2.8,0,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M100,1,0
1,0,0,-5.7,0,0,GO:1904018,positive regulation of vasculature development,M100,1,0
1,0,0,-3.6,0,0,GO:0043534,blood vessel endothelial cell migration,M100,1,0
0,1,0,0,-2.7,0,hsa04912,GnRH signaling pathway,M010,1,0
1,0,0,-4.6,0,0,hsa04390,Hippo signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0035023,regulation of Rho protein signal transduction,M100,1,0
0,1,0,0,-2.1,0,GO:0034109,homotypic cell-cell adhesion,M010,1,0
1,0,0,-2.3,0,0,GO:0021781,glial cell fate commitment,M100,1,0
1,0,0,-2.6,0,0,GO:0032733,positive regulation of interleukin-10 production,M100,1,0
1,0,0,-2.4,0,0,GO:0071277,cellular response to calcium ion,M100,1,0
0,1,0,0,-2.3,0,M60,PID NFAT TFPATHWAY,M010,1,0
0,0,1,0,0,-2.5,GO:0002274,myeloid leukocyte activation,M001,1,0
1,0,0,-3.2,0,0,GO:0001894,tissue homeostasis,M100,1,0
0,1,0,0,-4,0,R-HSA-389359,CD28 dependent Vav1 pathway,M010,1,0
1,0,0,-2.2,0,0,M281,PID FAK PATHWAY,M100,1,0
1,0,0,-5.6,0,0,WP2374,Oncostatin M signaling pathway,M100,1,0
0,0,1,0,0,-3.8,GO:0045055,regulated exocytosis,M001,1,0
1,0,0,-2.5,0,0,GO:0150064,vertebrate eye-specific patterning,M100,1,0
1,0,0,-2.9,0,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M100,1,0
1,0,0,-2.9,0,0,GO:0030336,negative regulation of cell migration,M100,1,0
0,1,0,0,-2.2,0,GO:0007596,blood coagulation,M010,1,0
1,0,0,-4.1,0,0,hsa04066,HIF-1 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M100,1,0
1,0,0,-4.1,0,0,GO:0043254,regulation of protein-containing complex assembly,M100,1,0
1,0,0,-2.8,0,0,GO:0090132,epithelium migration,M100,1,0
0,0,1,0,0,-2.6,GO:0006691,leukotriene metabolic process,M001,1,0
1,0,0,-2.2,0,0,GO:0032677,regulation of interleukin-8 production,M100,1,0
1,0,0,-5.5,0,0,GO:0032946,positive regulation of mononuclear cell proliferation,M100,1,0
1,0,0,-2.5,0,0,WP3596,miR 517 relationship with ARCN1 and USP1,M100,1,0
1,0,0,-2.2,0,0,GO:0072006,nephron development,M100,1,0
1,0,0,-2.4,0,0,GO:0060395,SMAD protein signal transduction,M100,1,0
1,0,0,-3,0,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M100,1,0
1,0,0,-3.5,0,0,GO:0050678,regulation of epithelial cell proliferation,M100,1,0
1,0,0,-3.2,0,0,WP2112,IL 17 signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:1903034,regulation of response to wounding,M100,1,0
1,0,0,-2.3,0,0,GO:0017145,stem cell division,M100,1,0
1,0,0,-3.4,0,0,GO:0051048,negative regulation of secretion,M100,1,0
1,0,0,-2.7,0,0,GO:0010594,regulation of endothelial cell migration,M100,1,0
1,0,0,-2.5,0,0,GO:0061072,iris morphogenesis,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1227990,Signaling by ERBB2 in Cancer,M100,1,0
1,0,0,-2.2,0,0,M212,PID INTEGRIN5 PATHWAY,M100,1,0
1,0,0,-3.2,0,0,GO:0022612,gland morphogenesis,M100,1,0
1,0,0,-2.3,0,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M100,1,0
0,1,0,0,-2.1,0,hsa05320,Autoimmune thyroid disease,M010,1,0
1,0,0,-3.3,0,0,GO:0070664,negative regulation of leukocyte proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0021762,substantia nigra development,M100,1,0
0,1,0,0,-2.4,0,GO:0030218,erythrocyte differentiation,M010,1,0
0,0,1,0,0,-3.4,GO:0030031,cell projection assembly,M001,1,0
1,0,0,-2.3,0,0,hsa05332,Graft-versus-host disease,M100,1,0
1,0,0,-4.2,0,0,WP75,Toll like receptor signaling pathway,M100,1,0
1,0,0,-2.6,0,0,R-HSA-9705671,SARS-CoV-2 activates/modulates innate and adaptive immune responses,M100,1,0
1,0,0,-2.4,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
1,0,0,-4.3,0,0,GO:0002237,response to molecule of bacterial origin,M100,1,0
0,0,1,0,0,-2.5,GO:0008654,phospholipid biosynthetic process,M001,1,0
1,0,0,-2.7,0,0,R-HSA-202733,Cell surface interactions at the vascular wall,M100,1,0
1,0,0,-2,0,0,GO:0046643,regulation of gamma-delta T cell activation,M100,1,0
1,0,0,-2.4,0,0,GO:0032648,regulation of interferon-beta production,M100,1,0
0,1,0,0,-2.1,0,GO:0043030,regulation of macrophage activation,M010,1,0
1,0,0,-2.9,0,0,GO:0031331,positive regulation of cellular catabolic process,M100,1,0
1,0,0,-2.3,0,0,GO:0034341,response to type II interferon,M100,1,0
1,0,0,-2.3,0,0,R-HSA-5218859,Regulated Necrosis,M100,1,0
1,0,0,-2.1,0,0,GO:0010507,negative regulation of autophagy,M100,1,0
1,0,0,-4.8,0,0,GO:0043122,regulation of canonical NF-kappaB signal transduction,M100,1,0
0,0,1,0,0,-2.3,R-HSA-1433557,Signaling by SCF-KIT,M001,1,0
1,0,0,-2.6,0,0,GO:0050729,positive regulation of inflammatory response,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9659379,Sensory processing of sound,M100,1,0
0,1,0,0,-2.2,0,hsa04148,Efferocytosis,M010,1,0
1,0,0,-2.9,0,0,GO:0046641,positive regulation of alpha-beta T cell proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0038154,interleukin-11-mediated signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:0021700,developmental maturation,M100,1,0
1,0,0,-2.7,0,0,WP1539,Angiogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0043086,negative regulation of catalytic activity,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1236975,Antigen processing-Cross presentation,M100,1,0
1,0,0,-3,0,0,WP2795,Cardiac hypertrophic response,M100,1,0
1,0,0,-3.5,0,0,GO:0048771,tissue remodeling,M100,1,0
1,0,0,-2.6,0,0,GO:0060749,mammary gland alveolus development,M100,1,0
1,0,0,-4.1,0,0,GO:0048864,stem cell development,M100,1,0
1,0,0,-3.4,0,0,R-HSA-5683057,MAPK family signaling cascades,M100,1,0
1,0,0,-2.5,0,0,GO:0038091,positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,M100,1,0
1,0,0,-3,0,0,WP4217,Ebola virus infection in host,M100,1,0
1,0,0,-2.8,0,0,GO:0048880,sensory system development,M100,1,0
1,0,0,-2.4,0,0,hsa04064,NF-kappa B signaling pathway,M100,1,0
1,0,0,-2.9,0,0,GO:0006953,acute-phase response,M100,1,0
1,0,0,-3.3,0,0,GO:0071396,cellular response to lipid,M100,1,0
1,0,0,-3.6,0,0,R-HSA-202403,TCR signaling,M100,1,0
1,0,0,-2.4,0,0,WP4205,MET in type 1 papillary renal cell carcinoma,M100,1,0
0,1,0,0,-2.8,0,GO:0021544,subpallium development,M010,1,0
1,0,0,-2.4,0,0,GO:0034614,cellular response to reactive oxygen species,M100,1,0
0,1,0,0,-2,0,GO:0048568,embryonic organ development,M010,1,0
1,0,0,-2.9,0,0,GO:0030225,macrophage differentiation,M100,1,0
0,0,1,0,0,-3.1,GO:0043299,leukocyte degranulation,M001,1,0
1,0,0,-2.8,0,0,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M100,1,0
1,0,0,-3.1,0,0,GO:0043065,positive regulation of apoptotic process,M100,1,0
1,0,0,-2.4,0,0,GO:0062197,cellular response to chemical stress,M100,1,0
1,0,0,-3.2,0,0,GO:0040013,negative regulation of locomotion,M100,1,0
1,0,0,-2.2,0,0,WP5101,Congenital generalized lipodystrophy,M100,1,0
1,0,0,-2.5,0,0,GO:1900223,positive regulation of amyloid-beta clearance,M100,1,0
1,0,0,-2.1,0,0,GO:0050885,neuromuscular process controlling balance,M100,1,0
1,0,0,-2,0,0,GO:0002483,antigen processing and presentation of endogenous peptide antigen,M100,1,0
1,0,0,-3.2,0,0,hsa04668,TNF signaling pathway,M100,1,0
1,0,0,-3.1,0,0,WP3931,Embryonic stem cell pluripotency pathways,M100,1,0
1,0,0,-2.8,0,0,GO:0043406,positive regulation of MAP kinase activity,M100,1,0
1,0,0,-3.5,0,0,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M100,1,0
1,0,0,-2,0,0,GO:0061045,negative regulation of wound healing,M100,1,0
1,0,0,-2.7,0,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M100,1,0
1,0,0,-2.2,0,0,R-HSA-448424,Interleukin-17 signaling,M100,1,0
1,0,0,-2.3,0,0,GO:0002503,peptide antigen assembly with MHC class II protein complex,M100,1,0
1,0,0,-3.5,0,0,GO:0001952,regulation of cell-matrix adhesion,M100,1,0
1,0,0,-5.6,0,0,GO:0002819,regulation of adaptive immune response,M100,1,0
1,0,0,-3,0,0,GO:0001914,regulation of T cell mediated cytotoxicity,M100,1,0
1,0,0,-2.3,0,0,GO:0002399,MHC class II protein complex assembly,M100,1,0
1,0,0,-2.7,0,0,GO:0061035,regulation of cartilage development,M100,1,0
1,0,0,-2.2,0,0,R-HSA-9664565,Signaling by ERBB2 KD Mutants,M100,1,0
0,1,0,0,-2.5,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M010,1,0
1,0,0,-2.3,0,0,GO:0032535,regulation of cellular component size,M100,1,0
1,0,0,-3.8,0,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M100,1,0
1,0,0,-2.3,0,0,GO:0062043,positive regulation of cardiac epithelial to mesenchymal transition,M100,1,0
1,0,0,-2.1,0,0,M223,PID BETA CATENIN NUC PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0032703,negative regulation of interleukin-2 production,M100,1,0
0,0,1,0,0,-3.6,GO:0002275,myeloid cell activation involved in immune response,M001,1,0
1,0,0,-4.5,0,0,GO:1901342,regulation of vasculature development,M100,1,0
1,0,0,-4,0,0,GO:0001649,osteoblast differentiation,M100,1,0
1,0,0,-2,0,0,GO:1903902,positive regulation of viral life cycle,M100,1,0
1,0,0,-2.2,0,0,GO:0032481,positive regulation of type I interferon production,M100,1,0
0,1,0,0,-2.1,0,GO:2000107,negative regulation of leukocyte apoptotic process,M010,1,0
0,0,1,0,0,-3.4,R-HSA-9607240,FLT3 Signaling,M001,1,0
1,0,0,-4.7,0,0,GO:0045444,fat cell differentiation,M100,1,0
1,0,0,-2.2,0,0,R-HSA-1250196,SHC1 events in ERBB2 signaling,M100,1,0
1,0,0,-2.4,0,0,GO:0032330,regulation of chondrocyte differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0008360,regulation of cell shape,M100,1,0
1,0,0,-2.5,0,0,GO:2000741,positive regulation of mesenchymal stem cell differentiation,M100,1,0
1,0,0,-2.9,0,0,WP2806,Complement system,M100,1,0
0,1,0,0,-3.9,0,GO:0098543,detection of other organism,M010,1,0
0,1,0,0,-2.7,0,GO:0030168,platelet activation,M010,1,0
1,0,0,-2.9,0,0,GO:0045859,regulation of protein kinase activity,M100,1,0
1,0,0,-3.1,0,0,WP437,EGF EGFR signaling pathway,M100,1,0
0,1,0,0,-3.1,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M010,1,0
1,0,0,-2.2,0,0,GO:0065005,protein-lipid complex assembly,M100,1,0
1,0,0,-4.6,0,0,GO:0042102,positive regulation of T cell proliferation,M100,1,0
1,0,0,-3,0,0,hsa05231,Choline metabolism in cancer,M100,1,0
1,0,0,-2.2,0,0,GO:0046631,alpha-beta T cell activation,M100,1,0
1,0,0,-6,0,0,GO:0048514,blood vessel morphogenesis,M100,1,0
1,0,0,-2.5,0,0,GO:0007264,small GTPase mediated signal transduction,M100,1,0
1,0,0,-2.2,0,0,GO:0070391,response to lipoteichoic acid,M100,1,0
1,0,0,-3.2,0,0,GO:0031334,positive regulation of protein-containing complex assembly,M100,1,0
0,1,0,0,-2.2,0,GO:2000060,positive regulation of ubiquitin-dependent protein catabolic process,M010,1,0
1,0,0,-2,0,0,GO:1903306,negative regulation of regulated secretory pathway,M100,1,0
0,1,0,0,-2.4,0,WP1992,Genes targeted by miRNAs in adipocytes,M010,1,0
1,0,0,-8.1,0,0,GO:0010562,positive regulation of phosphorus metabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0001892,embryonic placenta development,M100,1,0
0,0,1,0,0,-2.9,GO:0071621,granulocyte chemotaxis,M001,1,0
1,0,0,-2.1,0,0,WP5304,Cholesterol metabolism,M100,1,0
1,0,0,-3.4,0,0,R-HSA-5653656,Vesicle-mediated transport,M100,1,0
1,0,0,-2.4,0,0,GO:0050808,synapse organization,M100,1,0
1,0,0,-2.2,0,0,GO:0046718,viral entry into host cell,M100,1,0
1,0,0,-3.3,0,0,GO:0072103,glomerulus vasculature morphogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0045591,positive regulation of regulatory T cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0045668,negative regulation of osteoblast differentiation,M100,1,0
0,1,0,0,-4,0,CORUM:2529,"LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated",M010,1,0
0,1,0,0,-2.1,0,GO:0002719,negative regulation of cytokine production involved in immune response,M010,1,0
1,0,0,-2.3,0,0,hsa04210,Apoptosis,M100,1,0
1,0,0,-5,0,0,hsa04657,IL-17 signaling pathway,M100,1,0
0,1,0,0,-2.1,0,M252,PID IL8 CXCR1 PATHWAY,M010,1,0
1,0,0,-4.4,0,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
1,0,0,-2.1,0,0,WP5300,TROP2 regulatory signaling,M100,1,0
1,0,0,-3.6,0,0,GO:0042330,taxis,M100,1,0
1,0,0,-2.2,0,0,GO:0048762,mesenchymal cell differentiation,M100,1,0
1,0,0,-4.1,0,0,GO:0060760,positive regulation of response to cytokine stimulus,M100,1,0
0,1,0,0,-3.1,0,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M010,1,0
0,1,0,0,-2.2,0,GO:0002335,mature B cell differentiation,M010,1,0
1,0,0,-2.7,0,0,hsa04621,NOD-like receptor signaling pathway,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2173782,Binding and Uptake of Ligands by Scavenger Receptors,M100,1,0
0,1,0,0,-2.6,0,GO:0046629,gamma-delta T cell activation,M010,1,0
1,0,0,-2.5,0,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M100,1,0
1,0,0,-2.2,0,0,GO:0071223,cellular response to lipoteichoic acid,M100,1,0
1,0,0,-3.2,0,0,GO:0030866,cortical actin cytoskeleton organization,M100,1,0
0,1,0,0,-3,0,GO:0021537,telencephalon development,M010,1,0
1,0,0,-2.2,0,0,R-HSA-9665686,Signaling by ERBB2 TMD/JMD mutants,M100,1,0
1,0,0,-2.6,0,0,R-HSA-186797,Signaling by PDGF,M100,1,0
1,0,0,-2.9,0,0,GO:0150063,visual system development,M100,1,0
1,0,0,-2.6,0,0,GO:2000177,regulation of neural precursor cell proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0001776,leukocyte homeostasis,M100,1,0
1,0,0,-2.2,0,0,GO:1905709,negative regulation of membrane permeability,M100,1,0
1,0,0,-3.4,0,0,GO:0048872,homeostasis of number of cells,M100,1,0
1,0,0,-4.1,0,0,hsa04620,Toll-like receptor signaling pathway,M100,1,0
1,0,0,-2.9,0,0,WP3287,Overview of nanoparticle effects,M100,1,0
1,0,0,-2,0,0,GO:0036119,response to platelet-derived growth factor,M100,1,0
1,0,0,-2.3,0,0,WP4223,Ras signaling,M100,1,0
1,0,0,-2.9,0,0,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M100,1,0
1,0,0,-2.3,0,0,R-HSA-5675482,Regulation of necroptotic cell death,M100,1,0
1,0,0,-2.7,0,0,WP322,Osteoblast signaling,M100,1,0
1,0,0,-2.1,0,0,R-HSA-418594,G alpha (i) signalling events,M100,1,0
1,0,0,-5.2,0,0,GO:0007162,negative regulation of cell adhesion,M100,1,0
1,0,0,-2.1,0,0,GO:0043407,negative regulation of MAP kinase activity,M100,1,0
1,0,0,-3.4,0,0,GO:0045165,cell fate commitment,M100,1,0
0,1,0,0,-3,0,GO:1904888,cranial skeletal system development,M010,1,0
0,0,1,0,0,-2.6,GO:0002685,regulation of leukocyte migration,M001,1,0
1,0,0,-2.4,0,0,GO:0070741,response to interleukin-6,M100,1,0
1,0,0,-2.5,0,0,GO:0002477,antigen processing and presentation of exogenous peptide antigen via MHC class Ib,M100,1,0
0,0,1,0,0,-2,M50,PID PTP1B PATHWAY,M001,1,0
1,0,0,-2.5,0,0,GO:0010458,exit from mitosis,M100,1,0
1,0,0,-2.5,0,0,hsa04014,Ras signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:1903825,organic acid transmembrane transport,M100,1,0
1,0,0,-3.2,0,0,R-HSA-186763,Downstream signal transduction,M100,1,0
1,0,0,-2.1,0,0,GO:0001947,heart looping,M100,1,0
1,0,0,-3.5,0,0,GO:0043542,endothelial cell migration,M100,1,0
1,0,0,-3.2,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M100,1,0
0,1,0,0,-2.2,0,GO:0098926,postsynaptic signal transduction,M010,1,0
1,0,0,-2.2,0,0,GO:0045598,regulation of fat cell differentiation,M100,1,0
0,0,1,0,0,-2.7,WP5122,Prostaglandin and leukotriene metabolism in senescence,M001,1,0
0,0,1,0,0,-3.4,GO:0002263,cell activation involved in immune response,M001,1,0
1,0,0,-2.1,0,0,GO:0051235,maintenance of location,M100,1,0
1,0,0,-3.9,0,0,WP2877,Vitamin D receptor pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0002218,activation of innate immune response,M010,1,0
1,0,0,-2.1,0,0,GO:0010921,regulation of phosphatase activity,M100,1,0
1,0,0,-2.3,0,0,GO:0051100,negative regulation of binding,M100,1,0
1,0,0,-2.1,0,0,GO:0014910,regulation of smooth muscle cell migration,M100,1,0
0,1,0,0,-2.4,0,GO:0021756,striatum development,M010,1,0
1,0,0,-2.5,0,0,hsa04625,C-type lectin receptor signaling pathway,M100,1,0
